Potential commercial application of a bi-layer bone-ligament regeneration scaffold to anterior cruciate ligament replacement by Li, Jessica C. (Jessica Ching-Yi)
Potential Commercial Application of a Bi-Layer Bone-Ligament Regeneration
Scaffold to Anterior Cruciate Ligament Replacement
by
Jessica C. Li
B.S., Materials Science and Engineering
Cornell University, 2005
Submitted to the Department of Materials Science and Engineering
in Partial Fulfillment of the Requirements for the Degree of
Master of Engineering
at the
Massachusetts Institute of Technology
September 2006
MASSACHUSETTS INSTfE
OF TECHNOLOGY
OCT 0 2 2006
LIBRARIES
C 2006 Massachusetts Institute of Technology
All rights reserved
Signature of Author................. .................. ...... - ... ...... ....
Depa of Materials Science and Engineering
August 2, 2006
Certified by............... .. ....................... . ....... 
Lorna J. Gibson
Matoula S. Salapatas Professor of Materials Science and Engineering
Professor of Mechanical Engineering
Professor of Civil and Environmental Engineering
Thesis Supervisor
Accepted by .......................................... ....................... ............ • ...
Samuel M. Allen
POSCO Professor of Physical Metallurgy
Chair, Departmental Committee on Graduate Students
ARCHIVES

Potential Commercial Application of a Bi-Layer Bone-Ligament Regeneration
Scaffold to Anterior Cruciate Ligament Replacement
by
Jessica C. Li
Submitted to the Department of Materials Science and Engineering
on August 2, 2006 in Partial Fulfillment of the
Requirements for the Degree of Master of Engineering in
Materials Science and Engineering
ABSTRACT
A business model was created in order to explore the commercial application of a bi-layer bone-
ligament scaffold to the treatment of torn anterior cruciate ligaments (ACL) requiring
replacement. The two main keys in producing the bone scaffold are triple co-precipitation of
type-I collagen, chodroitin-6-sulphate, and calcium phosphate minerals and the use of
lyophilization to create a network where all the materials are homogeneously dispersed and
present in significant amounts. This process allows the creation of a porous network whose
physical characteristics, mechanical properties, and material content can all be changed to create
a scaffold that closely mimics natural bone. A collagen and chondroitin-6-sulphate scaffold is
used for ligament regeneration.
The ACL replacement market was chosen because it is one of the most commonly surgically
repaired ligaments in the body and because all of the current treatments have drawbacks. The
exercise of creating a business model made it clear that the commercial potential of starting a
company that focused on marketing a direct ACL replacement scaffold would most likely not be
successful mainly because surgeons would hesitate to use this product over current methods that
are satisfactory and it would be difficult to separate our product from other newer methods which
all boast similar advantages over current treatment options. However, the commercial potential
of using the technology to create a scaffold for graft site morbidity in certain ACL replacement
surgeries is large because there is no competition, and the implantation procedure for the surgeon
would be simple.
Thesis Supervisor: Loma J. Gibson
Title: Matoula S. Salapatas Professor of Materials Science and Engineering, Professor of
Mechanical Engineering, and Professor of Civil and Environmental Engineering
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Chapter 1. Introduction
One of the newer, more-hyped fields within the world of engineering is biotechnology.
Here, at the Massachusetts Institute of Technology, MIT, a new process to create a hard tissue
(bone) - soft tissue (cartilage or ligament) bi-layer scaffold was developed. The process, which
could conceivably be used at any hard tissue-soft tissue interface, is based on the triple co-
precipitation of collagen, glycosaminoglycan, and calcium phosphate, and subsequent
lyophilization to produce a scaffold with the desired pore structure. One particularly promising
commercial application of this technology is toward anterior cruciate ligament (ACL)
replacements. Currently, within the US, there are over 150,000 ACL replacement surgeries
every year; however, all treatments have their drawbacks, providing a good market for using the
scaffold as an implant to repair a torn ACL.
Description of the natural bone structure and remodeling process and the basic anatomy
of the knee will be followed by an explanation of the bone-ligament bi-layer scaffold production
process. The potential of utilizing this technology for a bone-ligament scaffold is highlighted
through a comparison between the scaffold and the natural structure. A business model was
developed with the help of OrthoMimetics Limited, a start-up company interested in the
commercial potential of the application of this technology to ACL replacement.
Chapter 2. The Human Body
Before any type of device can be developed to mimic or help the human body after injury
or disease, an understanding of the healthy body's function and structure is necessary. With this
knowledge, a suitable treatment can be devised and it can be determined whether the treatment is
working and how effective it will be. The device presented within this thesis will be used in the
treatment of ligament tears, and will explore the commercial viability of this device's application
specifically to a torn anterior cruciate ligament (ACL), one of the main ligaments in the knee.
Therefore, a brief background on the natural structure and function of the bone, the ligament, and
the bone-ligament junction will be followed by an anatomical description of the knee and other
body parts on which clinical trials of the device could be performed. Initial clinical trials would
be performed at sites where there was less of a load-bearing requirement on the device.
2.1 Bone
Within the body, two different types of bone can be found: compact and cancellous (see
Figure 1). Compact bone is most commonly found in the shaft of long bones. Cancellous bone
is found at the ends of long bones near joints and in the vertebrae. As this proposed bone-
ligament bi-layer scaffold is meant to be used at joints, the following description of natural bone
structure, growth, and remodeling will focus on cancellous bone.
Compact bone is a completely solid material, whereas cancellous bone is characterized
by a network of thin columns of bone, called trabeculae, with the spaces in between the
trabeculae being filled by blood vessels and red bone marrow, which produces blood cells. The
trabeculae form the outline of pores which have an average size of 300 - 400 jims. Osteocytes,
mature blood cells that help maintain the bone's daily metabolism, are located within the
trabeculae in hollow pockets called lacunae. The large volume of open space in cancellous bone
allows for a large degree of vascularization, meaning there are a lot of blood vessels present to
easily transport nutrients to the bone. In addition to blood vessels, nerve fibers running along
blood vessels adjacent to trabeculae have also been identified (Bilezikian, 2002). Osteoclasts,
cells that contribute to the resorption of bone, are found on the surface of the trabeculae. In the
case of cancellous bone located at the end of a long bone at a joint, the bone receives its nutrients
from a network of blood vessels entering the bone via the epiphyseal artery. The trabeculae of
cancellous bone located at joint are usually oriented perpendicular to the joint surface to provide
the bone with greater strength.
The mechanical properties of cancellous bone are usually anisotropic with greater
strength in the direction parallel to the trabecular orientation (See Section 3.2.5). Cancellous
bone is viscoelastic and, therefore, exhibits creep and stress relaxation behavior (Bilezikian,
2002). A viscoelastic material is one that will have different properties depending on the strain
rate at which testing occurs. Creep is the deformation of a material with time when subject to a
constant stress below its yield stress and is thought to act as a mechanism for energy dissipation
so that the bone can yield to stress without failing completely via bone fracture (Bilezikian,
2002). Stress relaxation is a decrease in stress when a material is held at the same strain. It is
thought that both the creep and stress relaxation behavior are due to bone's collagen content.
Cancellous Bone
Osteon
unmterentlal
Concentric
lamellas
Osteoblasts
Osteoclast
liamellae
Canllclus OsteocyteCanalicutuS
Figure 1. Comparison Between the Structure of Compact and Cancellous Bone. (Taken From Hall, 2003)
2.1.1 Bone Structure
Bone is a hard connective tissue, and like other connective tissue in the body, it is
essentially composed of widely separated cells embedded in an extracellular matrix, ECM. The
ECM defines the bone's structure and also performs most of the bone's functions, so interest will
be concentrated on the ECM. Bone's ECM can be described as a composite with organic and
inorganic components. The organic component is about 90% collagen, predominantly type I
collagen, by weight, with the rest being over 200 different non-collagenous proteins (Mann,
2001). The inorganic component is mainly hydroxyapatite (HA), a mineralized form of calcium
phosphate (CaP). The bone's flexibility comes from the collagen and its strength, stiffness, and
hardness come from the HA. The collagen is arranged in a very specific manner with multiple
layers of order, resulting in the bone's good mechanical properties. In its smallest form, collagen
is a long polypeptide chain, meaning it is made from a sequence of amino acids. The collagen
chain is comprised of amino acid triplet sequences of the following form:
-[-Gly-X-Y-]-,
where Gly represents the amino acid glycine, and X and Y represent other amino acids. One-
third of the time X and Y represent the amino acids proline and 4-hydroxyproline, respectively.
There are 338 of these triplets within a collagen chain, meaning each chain has the same chain
length (Mann, 2001). The regularity of the amino acid sequence gives the chain a repeating
structure that through steric constraints and interactions result in a twisting of the chain. Three
of these chains come together to form a triple-helix structure, commonly referred to as a
tropocollagen. These tropocollagens come together to form fibrils (see Figure 2). Within a
fibril, the tropocollagens line up end-to-end, a few tropocollagens in width. The spacing of the
tropocollagens within the fibril is precise, with a 40 nm gap, called the hole zone, between the
end of one and the end of the other (Mann, 2001). Further, the tropocollagen lying adjacent to
another tropocollagen will be offset by exactly 64 nm (Mann, 2001). This precise structure is
present to allow for the specific crosslinking between the ends of adjacent tropocollagens. The
hole zone is where growth of the HA begins. The exact process by which this occurs is unknown.
The HA crystals form all oriented in the same direction with their long axis oriented along the
length of the fibrils. Eventually the crystals grow to surround the entire fibril. It is this structure,
collagen fibrils embedded in HA, that makes up the trabeculae of the cancellous bone.
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Figure 2. Staggered Arrangement of Tropocollagens in a Collagen Fibril With Location of Crosslinks Drawn In.
(Taken From Irvine, 2006)
Proteoglycans and glycoproteins are two major groups of the non-collagenous protein
that constitute the rest of the organic portion of the ECM. Proteoglycans are characterized by the
attachment of long chain polysaccharide molecules to a central protein molecule. Long chain
polysaccharides are often called glycosaminoglycans, GAGs. Two common GAGs are
chondroitin sulfate and keratin sulfate, which are both "highly anionic and bind large numbers of
Ca 2 + ions," ( Mann, 2001). Glycoproteins are proteins with carbohydrate groups attached to
them. It isn't completely clear what role these proteins play but it is likely that they have an
important role in initiating and/or encouraging the growth of hydroxyapatite crystals.
2.1.2 Bone Formation and Remodeling
Bone is created within the body in three ways. The first two occur when bone is initially
forming throughout the first two decades of human life, while the third occurs once the initial
bone has formed, during the later years of human life.
Within a human embryo, the "skeleton" is comprised of mesenchymal cells, which are in
the shape of bones and are the sites where bone formation, or ossification, occurs. These
mesenchymal cells ossify either directly via intramembranous ossification or indirectly, via
endochondral ossification. In intramembranous ossification, bone is formed directly from the
mesenchymal cells. The flat bones of the skull are formed via this route. Long bones are usually
formed via endochondral ossification. In this process, the mesenchymal cells are first turned into
cartilage, which is then turned into bone. Intramembranous and endochondral ossification are
the first two ways in which bone is created within the body.
Remodeling is the third way bone is formed within the body and is particularly
interesting because it is the process that is the key to successful integration of an implant within
the body. The reason we call our implant a scaffold is because we hope that it will act as a
template upon which new bone will form, thereby integrating the implant into the existing bone.
We rely on the body's natural process of bone remodeling to allow this to happen. Remodeling
consists of the resorption and deposition of minerals and collagen by osteoclasts and osteoblasts,
respectively. The sequence of events during remodeling is as follows: origination of the
different cells involved in remodeling, activation of osteoclasts, resorption of old bone,
recruitment of osteoblasts, deposition of new bone matrix, and mineralization (Bilezikian, 2002).
The rate at which remodeling occurs is dependent on location within the body: bone at the end
of a long bone (cancellous) may be replaced every four months, whereas bone in the shaft of a
long bone (compact) may not be completely replaced within a person's lifetime. Further,
remodeling begins at the bone surface and cancellous bone has a much greater surface-to-volume
ratio than compact bone favoring cancellous bone remodeling. Remodeling within cancellous
bone starts occurring right after the bone is newly formed. Generally, the body will start bone
remodeling in response to stresses placed on the bone. If a particular joint is subject to heavier
loads, such as the knee or hip, the bones in this area will undergo far more remodeling than
bones in the fingers, which comparatively undergo less stress. In addition to just replacing old
bone, remodeling can also add bone to places. For example, if an inactive person starts running,
there will be a greater need for stronger bones, and more bone will be deposited than will be
resorbed. In contrast, if the bone is subject to no stresses, more will be resorbed than is
deposited. This reactive and adaptive remodeling of bone leads to changes in porosity, density,
orientation, and architecture, making each bone unique depending on its mechanical loading
history. It can also lead to a bone that has different properties in different directions because it is
subject to higher loads in one direction than another. A material that does not have the same
properties in all directions is anisotropic. Spontaneous remodeling also occurs to prevent the
build-up of old, brittle bone within the body.
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Figure 3. The Bone Remodeling Process that Occurs both Spontaneously and in Reaction to Stresses. (Taken From
University of Michigan, 2005)
2.2 Ligament
A ligament connects two bones to each other. It is composed primarily of collagen,
usually Type I, just as in bone. Other components include fibroblasts, cells found in connective
tissue that deposit the fibers and ground substance of the ECM, and some proteoglycans. As
compared to bone, there is a much lower amount of proteoglycan in a ligament. As in bone,
collagen arranges itself into fibers, which can either be parallel or branching and interwoven
(Mow, 1997). These fibers will then orient themselves along the long axis of the ligament,
which is also usually the direction in which the greatest amount of stress will occur. When a
ligament is subject to tensile forces, it usually exhibits a viscoelastic behavior, just like bone.
There are usually two distinct regions in a ligament's stress versus strain curve. There is a low
modulus region followed by a high modulus region. This is thought to occur because in the
relaxed state, the collagen fibers are in a "crimped" state. As noted earlier, collagen will form
into curled triple helices, meaning their backbones are not completely stretched out, resulting in a
collagen fiber that is "crimped". Upon initial straining, these fibers are stretched from their
completely curled-up helical state to a more stretched-out and elongated state. This does not
involve the stretching of any bonds and is relatively easy. As the fibers are stretched more,
however, the collagen fibers must rely on the stretching of covalent bonds in its backbone,
leading to an increase in the ligament's elastic modulus. Ligaments do not usually have as good
of a blood supply as bones do, with blood vessels located at the insertion site of the ligament to
the bone (Souryal, 2005). This makes internal upkeep and repair of ligaments harder than bones.
2.3 Bone-Ligament Junction
Replication of the bone-ligament junction is one of the problems that must be overcome
with all synthetic and scaffolding treatments to ACL injuries. A quick overview of this junction
will be given to help elucidate its importance and complexity. It has been found that the
ligament near a bone-ligament junction will undergo anywhere from two to four times more
elongation than the middle section of the ligament before it fails, or tears. This implies that the
stresses in this section of the ligament will be greater than in the middle section of the ligament
because as the ligament is stretched along one axis, it will shrink in the transverse directions.
This reduces the area over which the load is being carried, which increases the stress. The ends
of the ligament are able to withstand higher stresses without being damaged because there is a
transition through which the ligament becomes bone and the ligament is about three or four times
larger at the insertion point than at the middle of the ligament.
The gradual transition from a soft, pliable ligament to a hard, stiff bone helps to reduce
the concentration of stresses by strengthening the junction. The transition consists of four
distinct zones. Starting from the ligament, the first zone is just the ligament itself, consisting
mainly of type I collagen, with fibroblasts and proteoglycans. Very small blood vessels and
capillaries are also present. The second zone consists of fibrocartilage, a type of cartilage
containing numerous thick bundles of collagen fiber, where the main difference is that instead of
fibroblasts, there are fibrochrondrocytes, which are mature cells found in fibrocartilage. The
cells will gradually change shape from thin, flat fibroblasts to wider, rounder fibrochondrocytes,
making the border between these two zones indistinct. In the second zone, the collagen fibers
start to pack together more densely. The third zone consists of calcified fibrocartilage, and a
distinct line or "tide-mark" separates it from the second zone (Yahia, 1997). This tide-mark can
be very smooth or very irregular, but it is always very clear, making the transition from the
second zone to the third zone short and distinct. As the distance from the tide-mark and the
second zone increases, the number and size of mineral crystals (CaP) increase. Near the end of
the third zone, the crystals are large enough that they start to pack around the collagen, like in
bone, and it becomes hard to distinguish one crystal from another. The fibrochondrocytes
present in the second zone are still present in the third zone but they are now enclosed in lacunae,
which are surrounded by the crystals. The fourth and final zone is bone. These four zones can
be found to exist over a length of one millimeter. Two types of insertion sites exist, direct and
indirect. In direct insertion, both superficial and deep fibers are involved in the transition. In
indirect insertion, usually only deep fibers are involved and the second zone becomes very short
or may not exist at all.
2.4 The Knee
The knee is one of the most commonly injured joints in the body. This is due to the fact
that is one of the most highly stressed joints while also allowing a large degree of motion. Also,
the bones of the knee do not in any way directly contribute to the stability of the joint, placing
complete responsibility for stability on its associated ligaments, tendons, and muscles. This is in
direct contrast to the hip, another high-stress joint that also allows a lot of motion, which consists
of the meeting of the femur and the hip bone at a ball-and-socket joint. It is called this because
at the joint, the femur is spherical and shaped like a ball, whereas the hip bone is curved and
shaped like a glove or socket, allowing the femur to sit right in the pelvis. Even without the
surrounding connective tissue, the shape of the bones already gives the joint some stability. This
is not the case in the knee, where the femur essentially sits atop the tibia, like building blocks.
This increases the importance of the corresponding ligaments and muscles in maintaining the
knee's stability and allowing it to be functional.
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Figure 4. Anatomy of the Knee. (Taken From Medical Internet Solutions, 2001)
2.4.1 Anatomy
The knee is the connection between the femur of the upper leg and the tibia of the lower
leg. A third bone, the patella, is located in front of the femur and mainly provides protection to
the joint. The ends of the femur and tibia that meet to form the knee, the epiphyseal regions of
the bone, are cancellous bone which formed primarily via endochondral ossification (Carter,
2001). The knee is known as a synovial joint, which means that the ligaments, tendons, and
muscles surrounding it form synovial capsule around the joint. Within this capsule is synovial
fluid, which lubricates the joint to help reduce friction, absorbs shock, and provides nutrients to
and removes carbon dioxide and metabolic wastes from the avascular cartilage. Within the
synovial cavity of the knee there are actually three joints. As shown in both Figure 4 and
Figure 5, the femur and tibia actually meet at two points, the inner and outer side of the knee.
The femur's joint surface forms two bulges, which are called condyles, while the tibia's joint
surface has two indentations, also called condyles. The third joint is that between the patella and
the femur.
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Figure 5. Anterior View of Knee. (Taken From Medical Internet Solutions, 2001)
Both the end of the femur and the end of the tibia are covered in articular cartilage, which
is a thin layer of cartilage that provides a smooth, slippery surface between the two bones that
reduces friction and also helps to absorb shock. In addition to the cartilage between the bones,
there are also two menisci, which sit between the condoyles of the femur and tibia. The menisci
help the condoyles fit together as they are irregularly shaped, circulate synovial fluid, and help
absorb shock.
Both the anterior cruciate ligament, ACL, and the patellar tendon are relevant to the
proposed application of ACL replacement. The ACL (see Figure 5) attaches the front of the
tibia to the back of the femur. This prevents hyperextension of the knee and prevents the tibia
from moving too far forward. The ACL ranges in length between approximately 27 and 35 mm
and is about 1 cm in transverse diameter (Horn, 2006; Vunjak-Novakovic, 2004). The patellar
tendon (see Figure 4) connects the patella to the front of the tibia and serves to strengthen the
front of the joint, while holding the patella in place.
2.4.2 ACL Injury
Ligament injuries are called sprains and result when the ligament is stressed beyond its
normal capacity leading to over-stretching or tearing of the ligament (Tortora, 2005). Sprains
result from a fall, twist, or force to a joint that pushes it out of its normal position and tears the
surrounding ligaments. Sprains are classified by their severity, ranging from minimal stretching
for a Grade I sprain to complete tearing for a Grade III sprain. See Table 1 for complete
descriptions of the different sprains and specific symptoms for an ACL sprain. From Table 1, it
is evident that when the ACL is completely torn due to a Grade III sprain, the symptoms will be
noticeable and will interfere with a person's daily activities. Thus treatment is made necessary
under these circumstances, of which the most common is replacement of the entire ACL via a
surgical procedure (See Section 5.2). It is these cases, when a replacement surgery is needed,
where it is thought that our bi-layer bone-ligament scaffold can be used. The ACL is stretched or
torn in about 70% of all serious knee injuries (Tortora, 2005). In 2002, 175,000 ACL
replacement surgeries were performed within the US (OrthoMimetics, 2006).
Grade I * ligament is stretched but not torn
* knee does not feel unstable or give out during activity
* a little tenderness and swelling
Grade II * ligament is partially torn
* knee may feel unstable or give out during activity
* a little tenderness and moderate swelling
Grade III * ligament is completely torn into two parts
* knees feels unstable and gives out at certain times;
ligament cannot control knee movements
* tenderness but little pain; may be little or a lot of
swelling
Table 1. Description and Symptoms of the Three Grades of Ligament Sprains.
2.5 The Jaw
The jaw, or temporomandibular, joint, is a hinge joint formed by the mandible and
temporal bone. The main ligaments of this joint are the lateral (or temporomandibular) ligament,
sphenomandibular ligament, and the stylomandibular ligament (See Figure 6). The lateral
ligament is actually two short bands that help prevent displacement of the mandible. The
sphenomandibular ligament is a thin band, whereas the stylomandibular ligament is a thick band.
These latter two ligaments more closely resemble the ACL and would be ideal sites for a clinical
trial. In the case of a person who dislocates their mandible more than once, a surgical procedure
to shorten these two ligaments might be performed to prevent further dislocations. Instead of
shortening these ligaments, clinical trials of our bone-ligament bi-layer scaffold could be used to
completely replace the ligaments.
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Figure 6. a) Medial view of the jaw with the stylomandibular and sphenomandibular ligaments. b) Lateral view of
the jaw with the lateral (temporomandibular) ligament. (Taken From Gray, 1918)
2.6 The Shoulder
The shoulder joint is a ball-and-socket joint formed by the humerus of the upper arm and
the clavicle. Three main ligaments, the coracohumeral ligament, the glenohumeral ligament, and
the transverse humeral ligament, together form the articular capsule of the shoulder joint. In
addition to these ligaments are the coracoacromial ligament, the acromioclavicular ligament, the
trapezoid ligament, and the conoid ligament (See Figure 7). Unlike the knee, most of the
strength and stability of the shoulder comes from the surrounding muscles, with the ligaments
playing a secondary role. This means less load-bearing responsibility is placed on the shoulder
ligaments as compared to the knee ligaments. The most common injuries to the shoulder are an
injury to the rotator cuff and dislocation. Rotator cuff injury usually results from repetitive
motion during certain activities and is often characterized by a tearing of the supraspinatus
muscle tendon. As a tendon connects a bone to a muscle, this would not be an appropriate trial
place for the bone-ligament bi-layer scaffold. The shoulder is the most commonly dislocated
joint by adults and is generally the result of a fall. It is often the case that after a person
dislocates their shoulder once they are prone to dislocating it again, which may be a result of
permanently stretched ligaments that are no longer able to keep the joint in place. Some people
also have unusually long ligaments which allow for easily dislocated shoulders. In these cases, it
is possible that a replacement of the over-stretched or abnormally long ligaments could result in
a more stable shoulder joint that is less prone to dislocation, providing an excellent trial location
for our bi-layer bone-ligament scaffold.
Figure 7. Shoulder Anatomy. (Taken From Gray, 1918)
2.7 The Elbow
The elbow is a hinge joint formed by the humerus of the upper arm and the ulna and
radius of the lower arm. The two main ligaments comprising the joint are the ulnar collateral
ligament and the radial collateral ligament; both are thick, strong, and triangular-shaped (See
Figure 8 below). The most common upper limb dislocation in children is dislocation of the
radial head, which is usually caused by a strong pull to the forearm while it is extended. This
results when the head of the radius slides past and ruptures the radial annular ligament. The
radial annular ligament forms a collar around the head of the radius where the radius and ulna
meet. Chronic radial head dislocation may result in ligament reconstruction, for which our bone-
ligament bi-layer scaffold could be used in a clinical trial.
Figure 8. Elbow Anatomy. a) left-elbow joint, showing the ulnar collateral ligament and the radial annular
ligament b) left-elbow joint, showing the radial collateral ligament. (Taken From Gray, 1918)
Chapter 3. The Technology
3.1 The Bi-Layer Bone-Ligament Scaffold
The manufacture of the bi-layer bone-ligament scaffold will be based on two main
processes: co-precipitation and lyophilization. Neither of these processes, used alone or
together, are particularly unique in the field of scaffold-production, but slight modifications have
led to a new, patentable method of producing a scaffold containing both a hard and soft tissue
component. Triple co-precipitation of collagen, glycosaminoglycan (GAG), and calcium
phosphate (CaP) particles, with all three components present in considerable amounts and evenly
distributed amongst the entire network has been accomplished and is unprecedented (Lynn,
2005). Lyophilization refers to the process of freezing a solution and sublimating off the liquid
phase, leaving behind the solid phase. It is commonly used in the food industry to prevent the
growth of micro-organisms. For this process, it provides a simple way to control the pore sizes
of the resulting scaffold via processing parameters such as time and temperature (See Section
3.2.1). Further, it provides a simple way to connect the bone scaffold and ligament scaffold
layers to each other without the use of fixation devices (See Section 3.2.3). The basic steps to
produce the bone scaffold are as follows:
1. Blend type-I collagen and chondroitin-6-sulphate in phosphoric acid solution.
2. Add in calcium nitrate and calcium hydroxide.
3. Let solution/slurry mix for 24 hours.
4. Place solution into freeze-dryer for lyophilization.
5. Crosslink collagen with carbodiimide.
6. Hydrolytically convert calcium-phosphate minerals between phases.
The ligament scaffold is made in the same way except that calcium nitrate and calcium
hydroxide are not added to the solution, thereby eliminating precipitation of CaP minerals. The
CaP minerals provide the bone scaffold with increased mechanical properties that the ligament
scaffold does not require. For this reason, the bone scaffold can be thought of as the mineralized
scaffold and the ligament scaffold the unmineralized scaffold. This process results in the
production of a scaffold, not a final replacement. The purpose of a scaffold is not to exist
eternally within the body but to act as a skeleton upon which the body can rebuild itself. Initially,
the body's cells will migrate onto the scaffold, grow, and proliferate. Eventually, as part of the
body's normal bone remodeling process (See Section 2.1.2), the scaffold will be broken down
and replaced by the body.
The three main materials comprising the bone scaffold are type-I collagen, chondroitin-6-
sulphate (GAG), and a CaP mineral component. All three components were chosen, in part,
because they are components of natural bone and/or ligament and present no biocompatibility
issues (See Sections 2.1.1 and 2.2). Further, it has been found that inclusion of a GAG increases
the resulting structure's mechanical properties and improves the process-ability of the collagen
(Lynn 2005). Calcium phosphate also provides the additional advantages of being highly
osteoconductive, improving the scaffold's mechanical properties, and improving bonding
between the bone scaffold and natural bone. Osteoconductive materials are those through which
bone healing can be "conducted" by allowing attachment, movement, and growth and
proliferation of living bone cells.
The first three steps of the process are meant to combine all the necessary components
together and ensure they are homogeneously dispersed throughout the solution. An important
parameter to control during these initial steps is the pH. At high pH levels, the collagen will not
break down, which will prevent it from homogeneously mixing with the GAG. The pH of the
solution also affects the relative concentrations of the four polymorphs of phosphoric acid
(H3P0 4, H2PO4, HPO42-, and P0 43-), which in turn affects the chemical composition and amount
of CaP that will precipitate out of solution and onto the scaffold (Lynn, 2005). The fourth step,
lyophilization, turns the solution containing all the components into the scaffold. The fifth step
of crosslinking improves the mechanical properties of the scaffold and tunes the degradation
time of the scaffold in vivo (see Section 3.2.2). There are many phases of CaP and the phase that
precipitates out during the process is not the most ideal one, but it can be converted into the
desired phase during the sixth step (see Section 3.2.4).
3.2 Comparisons Between Human Body and Bi-Layer Scaffold
3.2.1 Controlling Pore Size During Lyophilization
An essential step of integration of the scaffold with natural bone is that the body's cells
be able to migrate and survive within the scaffold. Natural trabecular bone has pore sizes of
about 300 - 400 pmns. Theoretically, the more the scaffold can mimic the actual structure of
natural bone, the more likely full integration is to occur. For this reason, a very important aspect
of the scaffold is its pore size, which is determined during the freezing step of lyophilization.
Lyophilization, as explained earlier, is a two-step process during which a solution is frozen and
the ice is sublimated off. In the lab, the mixture of collagen, GAG, and CaP in phosphoric acid
is placed in a mold, which is then placed into a freeze-dryer. Figure 9 and Figure 10 illustrate
the processing conditions used and the phase changes of water during the processing,
respectively. Two important values labeled in Figure 9 are R, the cooling rate, and TF, the final
temperature. The slurry is placed in the freeze-dryer at room temperature. Its temperature is
then lowered at a constant rate, R, to the final temperature, TF. It is held at TF for several hours
to ensure complete solidification of the water.
The pore size of the resulting collagen/GAG/calcium phosphate network is determined by
the coarsening of ice crystals during the freezing of the water. Immediately after ice starts to
nucleate out of the water, coarsening of the ice crystals begins. Longer coarsening times result in
larger ice crystals, which lead to larger-sized pores. The time during which coarsening occurs is
the solidification time, which is illustrated graphically in Figure 11, and can be defined as the
time from when the slurry temperature reaches 00 C until it starts to decrease below 00 C.
Figure 9. Freeze-Dryer Temperature and Pressure During Lyophilization. (Taken From Lynn, 2005)
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Figure 11. Slurry Temperature During Lyophilization. (Taken From Lynn, 2005)
The schematic drawing below, Figure 12, shows the set-up during the freezing process,
with heat flow represented by the arrows. The cooling rate and final temperature refer to the
conditions of the freezer shelf, not the air nor the slurry. Specifically, temperature control is
maintained via the flow of refrigerant and heating fluid through the shelf.
SVurry
Mould
Refrigerant
rigerant.Outlet
Figure 12. Schematic of Freeze-Dryer Set-Up During Lyophilization. (Taken From Lynn, 2005)
There are three ways in which heat could escape from the slurry during solidification: (1)
through the top of the slurry and directly into the air, (2) through the sides of the mold, and (3)
through the bottom of the mold via the shelf. A majority of the heat flow is through the mold
bottom because the mold is very thin at the bottom and the shelf temperature is less than the air
temperature. For this analysis, all heat transfer will be assumed to occur through the bottom of
the mold. The solidification time will be determined by the mold material, the cooling rate, and
the final temperature.
Initially, a stainless steel mold was used during freezing of the slurry because the freezer
shelf is also stainless steel and it was thought that this would reduce the barrier to heat flow
between the mold and the shelf. When using a stainless steel mold while varying cooling rate
and final temperature, the largest attainable pore size was about 150 gms. This is well short of
the desired size of around 400 gms. Using a polymer (polysulfone) mold for the bone scaffold
led to pore sizes of 450 gms. The reason this change in material led to such a marked difference
in pore size can be explained through the use of the basic thermal conduction equation of heat
conduction between two objects:
_ kA(T2 -T) t ,where Eqn. I
L
Q= heat[J],
k = thermal conductivity [W/mK],
A= area of contact,
T2 = higher temperature,
T, = lower temperature,
t = time, and
L = distance between two objects
If all other parameters of the process are held constant and the molds are the same size, then the
only difference between a stainless steel mold and a polysulfone mold would be found in k, the
thermal conductivity of the mold. Using the information in Table 2 below, it can be shown that
about 64 times more heat would be withdrawn from slurry in a stainless steel mold as compared
to slurry in a polysulfone mold.
Stainless Steel
Polysulfone
k, thermal
conductivity [W/mK]
14 (Hndbk of Chem &
Phys, 2005)
0.22 (MatWeb, 2006)
Qsteel ksteel
Qps = kps
14
S0.22
Table 2. Values of Thermal Conductivity. = 63.6
However, our interest is in how this change in material would affect the solidification time. Eqn.
1 can be rearranged to show how time varies while everything besides the thermal conductivity
is held constant. In this case, Q would be the amount of heat withdrawn from the slurry during
the solidification process, as the molds should be identical in size and, therefore, in amount of
slurry to be frozen for the two processes. By comparing the two solidification times, it can be
found that the solidification time for slurry in a polysulfone mold is 64 times longer than slurry
in a stainless steel mold, leading to the larger pore sizes. A mold made from material with a
small thermal conductivity will slow the heat flow from the slurry and increase the slurry's
solidification time, which consequently increases the pore size of the scaffold.
It is also important to consider heat flow through the slurry itself and how that might
affect the solidification times in different parts of the slurry. In other words, will slurry located
farther from the freezer-shelf have a longer solidification time and thus larger pore sizes than
slurry located closer to the freezer-shelf? This is essentially a question of how quickly heat
flows through the slurry-mold interface as compared to through the slurry itself. This is
represented by a system's Biot number. If the Biot number is small (< 0.1), then the interface is
the primary barrier to heat flow and temperature gradients within the slurry are negligible,
meaning solidification times and pore sizes within different parts of the slurry are the same. It
has been shown that the Biot number of the ligament slurry is 6.4 x 103, which is less than 0.1
and indicates that the slurry-mold interface is indeed the primary barrier to heat flow and
temperature gradients within the slurry are negligible (Harley, 2006). The Biot number of this
system was calculated by assuming the slurry was essentially water because more than 90% of
the slurry is water by both both volume and weight. The bone slurry, like the ligament slurry, is
mostly water and it is likely a Biot number of less than 0.1 would still be found. Therefore, it
can be assumed that as long as the mold is not too thick, pore sizes in different parts of both the
ligament and bone slurry are the same.
The two other processing parameters that control the rate of heat flow from the slurry,
and hence the pore size, are cooling rate and final temperature. Qualitatively, it is observed that
when the cooling rate is fast and the final temperature is low, the pores will be long and needle-
like or too small. When the cooling rate is slow and the final temperature is high, scaffolds with
very large pore sizes are formed. Just from observation, it can be concluded that solidification
time and pore size are inversely proportional to the cooling rate and proportional to the final
temperature. The little available amount of quantitative data is shown in Figure 13. Although
the data clearly supports the qualitative observations, no mathematical relationship can be
determined due to the scarcity of data points.
By using a particular mold material, cooling rate, and final temperature, the pore size of
the bi-layer scaffold can be controlled so that it will be equal to that of natural bone's pore size,
thereby encouraging and providing the best chance of successful integration of the scaffold with
the pre-existing bone.
Cooling Rate Pore Size
(oC/min) (gims)
0.923 96
0.667 120
0.571 127
Final Temperature Pore Size
(K) (gms)
263.15 151
253.15 121
243.15 110
233.15 96
Figure 13. Qualitative Data Showing the Effect of Cooling Rate and Final Temperature on Pore Size. (Harley,
2006)
3.2.2 Crosslink Degradation, Remodeling, and Integration of the Bone
Scaffold Into the Natural Bone Structure
Crosslinking is necessary to the success of any collagen-containing biomaterial because it
affects the product's mechanical properties and degradation rate. As mechanical loading affects
the natural bone remodeling process (See Section 2.1.2), it also affects bone regeneration after
injury, such as after a surgical procedure. The frequency, magnitude, and direction of the
mechanical loading all can have an effect on the type of tissue that is created (cartilage,
fibrocartilage, bone, etc.) and its orientation. For this reason, the mechanical properties of the
implant immediately following implantation are crucial. The degradation rate is important
because it defines how long the implant will exist in vivo. It is desirable for this time to fit in
with the natural bone's remodeling cycle time providing the best chance for good integration of
the implant into the natural bone. Another consideration when choosing a crosslinking agent is
the toxicity resulting from release of residual quantities of the agent within the body. A low
degree of crosslinking will result in poor mechanical properties and a short device lifetime,
whereas a high degree of crosslinking will result in good mechanical properties and a long
device lifetime.
The crosslinking agent used in this process is carbodiimide, specifically 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDAC). Carbodiimides facilitate crosslinking by
activating carboxyl groups on collagen molecules and other bio-organics, which can then bond
with free amine groups on other collagen molecules. With this method, the carbodiimide itself is
not involved in the crosslink, resulting in a direct crosslink between the collagen molecules and a
reduced risk of toxicity. This process also has the advantage of not affecting the stability of the
CaP in regard to solubility and crystalline structure, unlike other common crosslinking methods.
Addition of N-hydroxysuccinimide (NHS) to the crosslinking solution can increase the degree of
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crosslinking. The carbodiimide crosslinking agent increases the strength and stiffness of the
bone scaffold and imparts some enzymatic degradation resistance. Figure 14 shows a
comparison of the compressive mechanical properties between the crosslinked bone scaffold
(labeled "mineralized collagen/GAG" in Figure 14) and natural bone.
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Figure 14. Comparison of compressive mechanical properties of EDAC-crosslinked mineralized collagen/GAG and
other materials. (Taken From Lynn, 2005)
The compressive properties of the scaffold in the wet state are important because it more closely
replicates its status once in vivo. Figure 14 shows that while there is a marked decrease between
the mechanical properties of the scaffold in the dry and wet state, the crosslinked bone scaffold is
still load-bearing in the wet state. This is in contrast to the ligament scaffold (labeled
"unmineralized collagen/GAG" in Figure 14) and the un-crosslinked bone scaffold, both of
which disintegrate and are non-load-bearing in the wet state. This stark difference in load-
bearing capabilities in the wet state underscores the ability of crosslinking to improve the
scaffold's mechanical properties. Please refer to Section 3.2.5 for further comparisons between
the mechanical properties of the scaffolds and the natural structures.
3.2.3 Creating the Seamless Interface
There are two methods with which the bone and ligament scaffold layers can be fused
together. The first method takes advantage of the fact that there is a density difference between
the two layers. The slurries can be layered on top of each other and then lyophilized. The
difference in density prevents the layers from completely mixing with each other. Some degree
of mixing will occur, but this is ideal for creating a gradual interface between the two layers,
which should lead to a stronger bond than a planar interface. In the second method, the two
layers are put through the lyophilization process and then bonded together by placing a thin layer
of slurry between the bone and ligament scaffold layers. This whole construction is lyophilized
again, with the thin layer of slurry acting as glue between the two layers. This process also
creates a gradual interface between the two layers. The gradual interface that can be obtained
with this process closely mimics the actual structure of a bone-ligament connection (See Section
2.3) and should impart higher strength to the junction than a planar interface would.
3.2.4 Mineral Component of the Scaffold
Two other important factors affecting the scaffold's mechanical properties, in addition to
the degree of crosslinking, are the amount of CaP mineral in the scaffold and the phase of the
CaP mineral material. The amount of mineral in the scaffold can be controlled by adding more
or less calcium nitrate and calcium hydroxide because the amount of CaP that forms is limited
only by the amount of calcium added, not by the amount of phosphorus from the phosphoric acid.
The phase of the CaP is important because different phases have different properties.
The three CaP phases relevant to this discussion are brushite, hydroxyapatite (HA), and
octacalcium phosphate (OCP). Brushite is the phase precipitated out during processing of the bi-
layer bone-ligament scaffold and HA is the phase found in natural bone and, likely, the desired
phase for our scaffold. A method of converting brushite into HA via the OCP phase has been
developed that can be conducted at low temperatures and that does not appear to affect any other
features of the scaffold. Stoichiometric HA (Calo(P0 4 )6(OH)2; Ca:P = 1.67) is rarely found in
vivo, due to the high degree of ion substitutions. Frequently, OH- is replaced by F-, Cr, or
carbonate, phosphate is replaced by carbonate, and Ca+ is replaced by Sr2+, Mg 2+, or Na+
(Johnsson, 1992). Due to these ionic substitutions, the Ca:P ratio in healthy natural bone may
range from 1.50 to 1.70 (Lynn, 2005). At one time, both brushite and OCP were thought to be
precursors to in vivo formation of HA, indicating that they may be good bone substitute materials,
but there is little evidence to support these theories. The first identifiable phase during in vivo
HA formation is amorphous calcium phosphate (ACP), which eventually transforms to biological
HA, though it is possible that during this transformation both brushite and OCP are intermediate
phases that form and disappear too quickly to be identified (Johnsson, 1992). However, OCP
(Cag(HPO 4)2(PO4)4*5H20; Ca:P = 1.33) is thought to be an ideal bone substitute material for the
following reasons: (1) OCP can be remodeled and replaced directly by newly formed bone,
possibly due to its structural similarities to HA, (2) OCP has been shown to have good
osteoconductive properties, and (3) OCP has been shown to be a good carrier for growth factors
(Lynn, 2005; Johnsson, 1992). On the other hand, many people believe brushite (dicalcium
phosphate dihydrate; CaHPO4*2H 20; Ca:P =1.00) is not a suitable bone substitute material
because of its high solubility, but there is no evidence to support this belief (Lynn, 2005). At this
time, further testing is necessary to determine which of these three or which combination of these
three CaP phases would lead to the best results once the scaffold is implanted. The use of the
term results is meant to encompass recovery time, the scaffold's mechanical properties, and time
before the scaffold becomes fully integrated into the natural bone structure, to name a few.
Conversion of brushite to OCP and OCP to HA is accomplished via hydrolytic
conversion, which means the conversion takes place in the presence of water. Precise control of
synthesis parameters is necessary during conversion of brushite to OCP, and they include a
temperature of 36.50 C, a pH of 6.67, and an initial brushite to water ratio of 74.4 g/L (Lynn,
2005). Complete conversion can be accomplished after 24 hours (Lynn, 2005). Synthesis of HA
from OCP is much less sensitive to processing parameters and can be fully completed within 36
hours (Lynn, 2005). This conversion method allows for any combination of the three calcium
phosphate phases to be created, because 100% conversion will not be obtained if the synthesis
time is less than 24 and 36 hours for OCP and HA, respectively.
3.2.5 Mechanical Properties
If this scaffold is to be successful, it should have mechanical properties that compare with
the natural structures. If the bone scaffold's mechanical properties are far inferior to that of the
natural, surrounding bone, it could lead to poor healing or perhaps complete failure of the
scaffold. At the same time, in the case of the bone scaffold, it is probably not necessary that the
mechanical properties equal that of natural bone, they must only be good enough to maintain the
necessary shape for the necessary time (until remodeling occurs). The mechanical properties
considered in this review are the tensile and compressive elastic (or Young's) modulus, ultimate
strength, and ultimate strain, which are measures of a material's stiffness, strength, and
stretchability, respectively. These three values are represented graphically in Figure 15. The
bone scaffold and ligament scaffold will be compared to their corresponding natural structures.
There is no comparison between the scaffold and natural bone-ligament junction because no data
for the scaffold was available and no data for the natural junction could be found.
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Figure 15. Typical stress-strain curve showing elastic modulus, ultimate strength, and ultimate strain. (Taken From
Best)
Experiments to determine the mechanical properties of bone have been conducted for
years. A literature review to gather as much data as possible was conducted to obtain values
against which the scaffold's mechanical properties can be compared. The review revealed that a
variety of factors affect bone's measured mechanical properties. Data can be obtained using
standard mechanical testing methods or using ultrasound. When mechanical testing is used, the
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rate of loading and the direction of loading on the bone have the two greatest effects. Bone is
viscoelastic, meaning it responds differently to different loading rates, and it is also anistropic
which means it has different properties in different directions. Specifically, bone will be stronger
in directions of higher loading. In terms of the specimen itself, factors such as whether it is
compact or cancellous bone, whether it is wet or dry, whether it is fresh or has been stored in
some way and the manner in which it has been stored (embalmed, frozen, etc.), its temperature,
the age of the person from which the specimen is taken, and from which part of the body the
specimen is from all affect the test results. It would be impossible to consider all these factors
when compiling the data. Instead five variables were defined before any data was used: bone
species (human), test method (mechanical), bone type (compact versus cancellous), loading
direction (parallel versus perpendicular to direction of highest loading), and the bone's hydration
state (wet versus dry). All data compiled for this comparison were from human bone tested
using mechanical methods. For both compact and cancellous bone, there were four categories
into which the data was divided (See Table 3).
Direction of Loading
Longitudinal versus Transverse
Table 3. Categories into Which the Bone Mechanical Property Data was Divided.
The bone scaffold of the bi-layer bone-ligament scaffold is meant to mimic cancellous
bone, as this is the type of bone usually found at joints; however, cancellous bone mechanical
properties are much harder to measure than compact bone mechanical properties. For this reason,
a review of both compact and cancellous bone mechanical properties will be given.
Mechanical property measurements of compact bone usually focus on long bones. In this
case, the longitudinal direction is parallel to the long axis of the bone, and the transverse
direction is perpendicular to the long axis, in both the radial and circumferential directions. The
mechanical property values in Table 4 were calculated by averaging all the values found during
the literature review; no data could be found for values left blank. A complete listing of all the
data can be found in Appendix A.
Tensile Elastic Modulus (GPa)
Tensile Ultimate Strength (MPa)
Tensile Ultimate Strain (%)
Compressive Elastic Modulus (GPa)
Compressive Ultimate Strength (MPa)
Compressive Ultimate Strain (%)
Longitudinal
Wet
16.50 [29]
102.79 [38]
1.77 [24]
15.42 [12]
148.26 [29]
1.71 [13]
Longitudinal
Dry
19.11 [4]
119.28 [5]
0.56 [2]
15.83 [3]
172.72 [8]
Transverse
Wet
12.80 [1]
29.98 [5]
0.70 [1]
7.73 [2]
132.81 [3]
5.00 [1]
Transverse
Dry
11.36 [1]
6.32 [1]
150.31 [6]
Table 4. Average of all Mechanical Property Values Found for Compact Bone. The Number in Brackets is the
Number of Data Points Used to Determine the Average Value. See Appendix A for All Data Found.
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Figure 16. The Effect of Hydration State (Wet vs. Dry), Direction of Loading (Longitudinal vs. Transverse), and
Type of Loading (Tensile vs. Compressive) on the Measured Values of Elastic Modulus and Ultimate Strength of
Compact Bone.
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The data confirms that the direction of loading (longitudinal versus transverse), the
specimen's hydration state (wet versus dry), and the type of loading (tensile versus compressive)
all affect the measured mechanical properties. Graphical comparisons of the effect these three
variables have on elastic modulus and ultimate strength can be found in Figure 16. The effect
these variables have on ultimate stress was not included because there was not enough data to
make the proper comparisons. The graphs indicate that the direction of loading has a far greater
effect than hydration state. Specimens loaded longitudinally have significantly and consistently
higher elastic moduli and ultimate strengths than those loaded transversely. In contrast, while
the graphs show that specimens in the dry state are stronger and stiffer, the difference is not very
large and sometimes the wet specimen is stronger or stiffer. A comparison between the stress-
strain curves of wet and dry specimens was given by Elices (2000) and is reproduced in Figure
17. The curves show that while the dry specimen is slightly stronger and stiffer, the largest
difference between a dry and a wet specimen may come in the ultimate strain, as the wet
specimen can stretch up to three times more before failure. This is where the advantages of
having collagen as a component in bone are evident. The CaP mineral content gives bone its
strength and stiffness, but the collagen gives it its flexibility and stretchability, especially when
in a hydrated condition.
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Figure 17. Comparison Between a Dry and Wet Specimen's Stress-Strain Curves. (Taken From Elices, 2000)
In terms of a tensile or compressive stress, the graphs show that stiffness is greater under
a tensile load but that strength is greater under a compressive load. Further, the difference
between a tensile or compressive force is much greater for strength than for stiffness. In
particular, in the transverse direction, the compressive strength is much greater than the tensile
strength. This seems to result from the fact that while the tensile strength decreases significantly
when the bone is loaded transversely as opposed to longitudinally, the compressive strength
decreases only marginally. This difference in strength makes sense if one considers the fact that
there is really no situation where a long bone would be subject to direct tensile forces in a
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transverse direction, but that all ligaments or tendons pulling on the bone would pull in the
longitudinal direction. During torsion, or twisting, the bone does experience forces in the
transverse direction but they will not be acting to directly stretch the bone along a transverse axis.
Due to this lack of direct tensile loads in the transverse direction, the bone has no reason to
strengthen itself and is significantly weaker along the transverse axis.
Cancellous bone is a very different material and has very different mechanical properties
than compact bone, due to the trabeculae network. Whereas compact bone is a solid, continuous
material, much of the volume of cancellous bone is air. Not only does this structure make
cancellous bone hard to test, it also results in a wide range of measured mechanical properties.
Most discussions of cancellous bone mechanical properties focus exclusively on compressive
data because cancellous bone is generally subjected to compressive loads within the body and
because cancellous bone is more prone to crumble when gripped during testing than compact
bone. The mechanical properties of cancellous bone are highly dependent on two things: the
apparent density of bone and the direction of loading relative to the direction of the trabeculae.
The apparent density of bone is the mass of the bone tissue divided by the volume of the
specimen, bone and marrow space, and will further be referred to as density. The manner in
which the properties of cancellous bone depend on the direction of the trabeculae is equivalent to
how the properties of compact bone vary depending on whether the specimen is loaded
longitudinally or transversely. However, the effects of density are much greater and the effect of
the trabeculae direction will not be discussed further. This discussion of cancellous bone
mechanical properties refers only to wet bone, as no data was found for dry bone.
The remodeling process that is constantly occurring in cancellous bone (See Section 2.1.2)
gives rise to bone with a large range of densities, 0.1 g/cm3 to 1.0 g/cm3 (Mow, 1997).
Numerous studies have been conducted to determine how exactly density affects the mechanical
properties, and all have shown that the relationship can be represented with power law equations
(Currey, 2002; Mow, 1997). The compressive ultimate strength can be described by a power law
equation of the following form:
auft,c = Ap B  ,where Eqn.2
o•ut,c = compressive ultimate strength,
p = apparent density,
A = constant, and
B = constant, generally accepted to be 2.
The compressive elastic modulus can be described by a similar power law equation, though some
studies report proportionality to the square of the density and others the cube of the density. One
explanation of this discrepancy has been that the relationship changes from square to cubic at
higher densities (Currey, 2002). Two examples of plots of these relationships are shown in
Figure 18 and Figure 19. While the two examples both illustrate the power law relationships,
they still give widely varying ranges for modulus and strength. Specifically, the graphs in
Figure 18 show a significantly higher value for both strength and modulus at the same densities
as the graphs in Figure 19. An interesting fact about these power law relationships is that if
compact bone were also plotted (density - 2 g/cm 3) it would fall on a continuation of the
cancellous distribution (See Figure 19).
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Figure 18. Effect of Density on the Mechanical Properties of Cancellous Bone. (Taken From Mow, 1997)
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Figure 19. Effect of Density on the Mechanical Properties of Cancellous Bone. Note the Inclusion of Compact
Bone Data in the Upper Right Hand Corner of Both Graphs. Open Circles: Bovines; Solid Circles: Humans.
(Taken From Currey, 2002)
Density (g/cm )
Compressive Elastic Modulus (GPa)
Compressive Ultimate Strength (MPa)
Compressive Ultimate Strain (%)
Minimum
Value
0.08
0.004
0.10
1.1
Average
Minimum
Value
0.245 [7]
0.0356 [7]
0.4411 [6]
1.575 [4]
Maximum
Value
1.17
2
90
28.9
Average
Maximum
Value
0.979 [7]
0.8169 [7]
24.11 [6]
10.775 [4]
Table 5. Absolute and Average Minimum and Maximum Values for Cancellous Bone Properties. The Number in
Brackets is the Number of Data Points Used to Determine the Average Value. See Appendix B for all Data Found.
Due to the large range of mechanical property values that can be measured for cancellous
bone it is not practical to list an average value of all data that was found, as was done for the
compact bone data. Instead, the absolute and average minimum and maximum values from all
the data sources are shown in Table 5. The average values are included because the absolute
values will include data that could be considered "outliers" because they are very different from
the other sources. The data provides a good idea of how much cancellous bone properties can
vary and how much stiffer and stronger compact bone is compared to cancellous bone. All
cancellous bone mechanical property data can be found in Appendix B. The differences in
cancellous and compact bone mechanical property are also visible by considering their stress-
strain curves (See Figure 20). The stress-strain curve for cancellous bone can usually be divided
into three sections: an elastic region, a plateau region, and a densification region. During the
elastic region, the bone exhibits typical elastic properties. The plateau region is a result of the
continuous fracturing of more and more trabeculae, and is characterized by a flattening of the
stress-strain curve. These trabeculae eventually fill up all marrow spaces, so further loading is
associated with an increase in the modulus as the remains of the specimen are crushed.
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compression compact bone is significantly stiffer and stronger than cancellous bone, but that
cancellous bone is able to undergo more strain before failure. There is no data for the tensile
properties of cancellous bone but one can assume that relative to compact bone it is the same as
the compressive properties: its strength and stiffness will be less but its ultimate strain will be
greater.
Unfortunately, at this time, little testing has been done on the bone scaffold. The best
results obtained at this time are shown in Table 6. Typical stress-strain curves for the dry and
wet bone scaffold are shown in Figure 21 and Figure 22, respectively.
Dry Bone Scaffold Wet Bone Scaffold
Compressive Elastic Modulus (kPa) 762 4.12
Compressive Ultimate Strength (kPa) 85.2 0.29
Table 6. Best Reported Mechanical Properties for the Bone Scaffold. (Lynn, 2006)
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Figure 21. Typical Stress-Strain Curve for a Dry Bone Scaffold. (Taken From Lynn, 2006)
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The stress-strain curves show that, like cancellous bone, the bone scaffolds experience an
elastic, plateau, and densification region. This indicates that the scaffold has a similar structure
to that of cancellous bone; specifically, they are both porous materials. The dry scaffold has a
stiffness and strength two orders of magnitude greater than the wet scaffold whereas for compact
bone the dry bone was stiffer and stronger than the wet bone but was still within the same order
of magnitude. Compared to the average minimum cancellous bone mechanical properties (from
Table 5), the wet bone scaffold's modulus is four orders of magnitude less and its strength is
three orders of magnitude less. Compared to the average maximum cancellous bone mechanical
properties (from Table 5), the bone scaffold's modulus and strength are both five orders of
magnitude less. The similar stress-strain curves, but the obvious differences in mechanical
properties indicate that though the scaffold and natural bone may share structural similarities, the
intricacies of the bone structure are still not being well-modeled by the scaffold. Natural bone's
superior mechanical properties and its ability to maintain these properties once hydrated
probably result from a difference in the CaP mineral since it is this component of bone that gives
bone its strength and stiffness. Specifically, the differences may result from a higher CaP
mineral content in natural bone than in the scaffold, from less soluble CaP present in natural
bone than in the scaffold, or both. At this time, the bone scaffold is still in development, and it is
thought that by having a greater amount of CaP precipitates, adjusting the crosslinking, and using
various other methods, significant improvements can be made to the bone scaffold's mechanical
properties. It is unclear if these changes can lead to mechanical property values that are three to
five orders of magnitude greater than what they are now. However, even if this is not possible,
the actual mechanical property requirements of the scaffold are that they maintain their shape for
a certain amount of time, which means that its mechanical properties need not match those of
natural bone. The exact mechanical property values that correspond with this requirement are
unknown and may only be determined through testing. Another possible difference between the
scaffold and natural bone is the anisotropy of the mechanical properties. Currently, the process
used to make the scaffold creates a homogeneous structure that likely has the same properties in
all directions. At this time there is no data to either confirm or deny this. This is in direct
contrast to natural bone which is usually stronger in one direction. However, it is unclear how
much, if it all, this would affect the scaffold's ability to integrate itself into the natural bone
structure.
Mechanical property data for ligaments or tendons, which have a similar structure and
presumably similar mechanical properties to ligaments, is relatively scarce. Further, the data that
is available are usually from non-human specimens. Currey (2002) gave a brief comparison
between the mechanical properties of human tendon and bone (See Table 7), revealing that bone
is much stiffer and stronger than tendon but tendon has the ability to stretch much more before
failure. A typical stress-strain curve for tendon is seen in Figure 23 and shows strains of 10%
before failure.
Bone Tendon
Ultimate Tensile Strength (MPa) 150 100
Tensile Elastic Modulus (GPa) 20 1.5
Density (kg/m3) 2000 1200
Table 7. Comparison of Properties Between Bone and Tendon. (Currey, 2002)
Figure 23. Typical Tensile Stress-Strain Curve for Tendon. (Taken From Wainwright, 1982)
Despite the lack of data on the mechanical properties of ligaments and tendons in general,
due to the large number of ACL injuries, data for the mechanical properties of the ACL itself
was obtainable. Due to the varying thickness of the ACL along its length, stiffness and strength
are usually given in the units N/mm and N, respectively. A review of the data showed that the
generally accepted values for ACL tensile stiffness and ultimate tensile strength in a human knee
were 182 N/mm and 2,160 N, respectively (Vunjak, 2004; Johnson; Wheeless). Compressive
data for the ACL was not available and also is not very important because it does not usually
undergo compression in the body. Further, the ACL, and other ligaments, fail because they are
stretched too far in response to a tensile stress, not because they become too compressed.
Unfortunately, a good technique has not yet been devised to test the tensile properties of
the ligament scaffold. The compressive properties of the scaffold however are easily obtained
and are shown in Table 8, which gives values for the elastic modulus, the elastic collapse stress,
and the elastic collapse strain of the wet ligament scaffold. This data comes from Harley (2006)
and is the maximum value reported. A complete analysis of how these values are affected by
pore size, crosslink density, and relative density can be found in Harley (2006). The elastic
collapse stress and strain are very different from the ultimate stress and strain. A typical stress-
strain curve for the ligament scaffold is shown in Figure 24, with the collapse stress and strain
marked as Gel* and Eel*, respectively. The elastic collapse stress and strain signify when the
elastic region ends and the plateau region begins. This stress-strain curve looks more like the
cancellous bone stress-strain curve (Figure 20) than a tendon or ligament stress-strain curve
(Figure 23), with an elastic, plateau, and densification region. This is because the ligament
scaffold has a similar porous structure as cancellous bone.
Compressive Elastic Modulus (Pa) 1497.6
Compressive Elastic Collapse Stress (Pa) 75.39
Compressive Elastic Collapse Strain (%) 8.3
Table 8. Maximum Mechanical Property Values for the Wet Ligament Scaffold. (Harley, 2006)
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Figure 24. Typical Stress-Strain Curve for the Ligament Scaffold. The elastic modulus (E), elastic collapse stress
(oaI*), and elastic collapse strain (eel*) are all shown. (Taken From Harley, 2006)
While this data cannot be directly compared to the reported values of ligament
mechanical properties due to the different loading directions (tension versus compression), the
different types of stress and strain reported (ultimate versus elastic collapse), and the use of
different units (N and N/mm versus Pa), it still shows that the ligament scaffold's stiffness and
strength are still well below that of a natural ligament. In the case of compact bone, the tensile
and compressive elastic moduli were within an order of magnitude of each other. If this can also
be assumed of the ligament, then one would expect the compressive elastic modulus to be around
1 GPa (since the tensile elastic modulus is 1.5 GPa, from Table 7), however, the ligament
scaffold has a compressive elastic modulus of 1.5 kPa, a difference of six orders of magnitude.
Another difference is that Harley (2006) reports that the ligament scaffold is isotropic, which
means the direction of loading will not affect the measured mechanical properties. This is very
different from a natural ligament which is meant for loading in one direction and is significantly
stronger and stiffer in this direction. The one good thing is that the ligament scaffold does seem
to be able to withstand a significant amount of strain before failure; however, how this will
change when the scaffold is subject to a tensile stress as compared to a compressive stress is
unknown.
Clearly, significant improvements in both the bone and ligament scaffold are needed
before they can match that of natural bone and ligament. Even if the scaffold does not have to
match the properties of the natural structure, improvements are still needed. In the case of the
bone scaffold, there are still specific, known steps that can be taken to improve the properties,
and it is thought that they can be improved to meet the implant requirements, but they might not
necessarily match that of natural bone.
Chapter 4. Intellectual Property
4.1 Review of the IP Space
A review of the IP area surrounding this new process was conducted from two angles.
The first was to look at existing scaffold patents and the second was to look at other bone,
ligament, bone/ligament, and bone/cartilage replacement patents. An initial search of collagen
scaffold patents resulted in thousands of relevant patents, which would have been impossible to
sort through. Clearly, a more organized approach was necessary to find any relevant patents.
The research leading to the development of this bone-ligament scaffold production process
started years ago with a collagen scaffold for skin regeneration. Patents related to this scaffold
and any subsequent patents were reviewed first. The search then focused on the two main
processing steps to create our scaffold: co-precipitation with calcium phosphate and
lyophilization, or freeze-drying. Searching for patents geared toward bone, ligament,
bone/ligament, and bone/cartilage replacements proved much easier as there were significantly
less of them. The reason a search for patents regarding bone, ligament, and bone/ligament
replacements is fairly obvious as this is the proposed application of the bi-layer scaffold
described herein. It was also decided to search for bone/cartilage replacements because cartilage
and ligaments are both soft tissues and it is possible that a technology designed for one could be
applied to the other, as our technology could. A complete list of all patents described below and
other relevant patents found during the search can be found in Appendix C. The inventor name,
claim date, patent number, and other information are included.
4.1.1 Skin-Regeneration Scaffold and Subsequent Patents
The aforementioned skin-regeneration scaffold, the proposed bone-ligament scaffold, and
anything coming in between the two were developed in the lab of Dr. Ioannis Yannas. The
search for patents related to the skin-regeneration scaffold and any subsequent research was done
by finding patents with Dr. Yannas listed as an inventor.
It was found that most of the patents applied specifically to skin-regeneration scaffold
processing, placing them outside of the pertinent IP space. Further, the first patent was filed in
1977 and a number of the subsequent patents were also filed more than 20 years ago, taking them
completely out of the IP space. Nevertheless, a description of some of the patents will be given,
mainly to illustrate the similarities between the processes and materials used between a scaffold
for skin and for bone, which seem to be two very different products. First off, this says that
patents for any type of scaffold could potentially impose on the IP space our process and product
would inhabit. Secondly, the fact that these patents are relatively old but still do in some ways
overlap the bone-ligament's scaffold IP space indicate that lots of the research in making
scaffolds is still based on an old idea of a collagen scaffold but have just added to it or modified
it in some way and it is very possible that one of these variations would be in our IP space.
The first patent (US Patent No. 4060081) filed was for the specific application of
"synthetic skin" comprising a "multilayer membrane," where the first layer is made from a
"crosslinked collagen-mucopolysaccharide composite", such as chondroitin-6-sulfate and the
second layer is made from a natural or synthetic polymer. One patent (US Patent No. 4280954)
dealt with a specific method of cross-linking the collagen and mucopolysaccharide using an
aldehyde. Another patent (US Patent No. 4522753) dealt with preserving the porosity of a
scaffold via freeze-drying.
4.1.2 Further Patent Search
A detailed description and closer analysis of two of the other relevant patents found from
the subsequent patent search follows.
US Patent No. 6887488: Nano-calcium phosphates/collagen based bone substitute materials
This patent describes a CaP/type-I collagen composite arranged in layers to form a
laminar structure. The composite is made by mixing the components in acetic acid until the
collagen and CaP co-precipitate out of solution and then freeze-drying the solution. The
resulting composite is then ground into a fine powder which will be dispersed and used as
reinforcement on a polymer matrix. It is geared toward the treatment of bone defects and bone
fractures.
First off, this patent describes a process that includes the two most important steps in our
process: co-precipitation and freeze-drying (lyophilization). During the patent search, it became
clear that these two steps are not particularly unique in the world of scaffold research. A number
of patents used one or the other and some, such as this one, used both. In addition, this patent
describes the co-precipitation of collagen with CaP particles, which is a cornerstone of our
product, as it is believed that by refining the exact ratio of CaP to collagen and GAG, a scaffold
with the same mechanical properties as natural bone can be produced. Despite these similarities,
a number of differences keep this patent separate from our process and product. They include
the fact that our process includes the use of GAG, differences in the compounds from which the
CaP particles will be formed, the fact that our composite is not laminar, and, most of all, that this
patent describes a polymer-based scaffold.
US Patent No. 6077989: Resorbable implant biomaterial made of condensed calcium phosphate
particles
This patent describes a biodegradable implant specifically for the use of connecting soft
and hard connective tissues. The implant would be made of interconnecting CaP particles which
would form an interconnected network of free space starting from the outer surface of the
implant and existing within the entirety of the implant's interior. Parameters for the CaP phase
and networks pore size are given. The network is strengthened via biodegradable polymers.
Cells from any type of soft tissue, including ligaments, can be seeded and allowed to grow within
the soft tissue connective portion in vitro.
This patent was interesting because it focused on the problem of attachment between soft
and hard connective tissue. Our bone-ligament scaffold also focuses on this problem and claims
a seamless interface between the soft and hard connective tissue. This patent describes an
implant that also hopes to do this. The basic idea behind both of the scaffolds is a continuous
network spanning from the hard tissue to the soft tissue, hopefully creating a gradual change in
structure from one tissue type to the next. Beyond this, though, there are differences: the
implant described in this patent doesn't include an actual scaffold for the soft tissue and the
scaffold is made from a network of CaP particles, whereas our scaffold consists of a network of
collagen and GAG with CaP particles embedded within it. The use of a CaP network is also
notable because it again illustrates the use of CaP to provide greater strength to a scaffold.
4.1.3 Bone Regeneration Scaffold Patents
The patents found during this search seemed to fall into three categories: (1) use of CaP
as the main component in a resorbable bone repair device, (2) seeding of living material, such as
cells, proteins, and DNA, onto a matrix to encourage bone growth into the device, and (3) other
processing techniques. An example of each will be given below. The common thread amongst
almost all of the reviewed patents was the use of CaP or living material to encourage integration
of the device into the natural bone structure. One patent (US Patent No. 5522895) that did not
include either of these was one that described a biodegradable, biocompatible template made
from a biodegradable synthetic polymer matrix and a pore-creating substance dispersed within
the matrix. The proposed device would be suitable for bearing mechanical loads while also
providing a guide for natural bone re-growth at an injured site.
US Patent No. 6972130: Bioceramic Compositions
This patent describes a bioceramic composite comprised primarily of poorly crystalline
apatite (PCA) CaP and biologically active agents, such as tissue-degrading or tissue-forming
cells. The main application for this device would be cell and drug delivery to bony sites. The
primary goal of the device is protecting the drugs in vivo until they reach the desired destination
and then controlling the release kinetics of the drugs. The degradation rate of the device, which
affects the drug's release kinetics, can be controlled by changing the device density, including an
"erosion rate modifier", and seeding the device with osteoclast and macrophage cells, which
digest bone. One of the other applications mentioned within the patent is for "bone production
and healing". In this case, the device would be seeded with bone-forming cells, preferably from
the person receiving the implant, or the precursor of these cells so that ossification would occur
within four to twelve weeks.
The application towards bone production and healing is most relevant to this patent
search. The patent describes an implantable bone regeneration scaffold that will be completely
integrated into the natural bone structure via the body's natural remodeling process due to the
use of CaP. This is exactly the premise on which our bone scaffold is based. The main
difference between the two scaffolds would be the components other than CaP. This patent
describes a device that relies heavily on the seeding of living cells, whereas our scaffold contains
no living cells. Another difference between the two scaffolds is the type of calcium phosphate
used; PCA for theirs and brushite, HCP, and/or HA for ours. This patent further emphasizes the
fact that many people are trying to use CaP-based or CaP-augmented scaffolds to induce better
integration with natural bone once the device is placed in vivo.
US Patent No. 6919308: Osteogenic Devices
This patent describes a device that will induce endochondral ossification by seeding
osteogenic proteins onto a matrix composed primarily of collagen. An osteogenic substance is
one that induces bone formation. The matrix will be biodegradable and have pores that allow
"influx, differentiation, and proliferation of migratory progenitor cells." Most of the claims
focus on the osteogenic protein, not the collagen matrix.
This patent is relevant because it specifically focuses on the application of bone growth
using a collagen matrix. However, it should not interfere with our bi-layer scaffold because of
the inclusion of osteogenic proteins in the scaffold and because it does not describe a process to
make the collagen scaffold itself.
US Patent No. 6530958: Tissue Regeneration Matrices by solid Free-Form Fabrication
Techniques
This patent describes the production of a tissue and bone scaffold made from either
biocompatible polymers, composite powders, or both, primarily using the method of 3-D printing.
The patent focused on bone scaffolding and within its claims described a specific 2 cm x 1 cm x
1 cm rectangular device for bone regeneration. The claims focus on the use of a 3-D printing to
create the devices and the components of the devices. For the bone scaffolding, the main
component would be a resorpable powder of CaP, HA, calcium carbonate, or some combination.
Other components include a biocompatible polymer, a binder to help the polymer bond to the
scaffold, and a bioactive agent, such as HA crystals. The claims also describe the structure of the
printed scaffold as having pore sizes from five to forty microns in diameter and walls less than
100 pms thick.
This patent shows that even if similar materials are used, such as calcium phosphate, if a
novel processing technique is developed, a patent will be granted. For our scaffold, it has
already been shown by the patent review that the materials we use are definitely not novel, so we
are relying on the processing technique used to form these raw materials into a scaffold to obtain
our patent.
4.1.4 Artificial Ligament Patents
As noted earlier, far fewer patents were found using this approach. A number of the
patents were filed by companies targeted as competitors to our proposed product. These patents
are reviewed later in Section 5.3, when the competitors are identified. It will be said now,
though, that none of these patents or any of the other patents found in this search would seem to
be a roadblock for the patenting of our process because most patents pertained to allografts,
xenografts, polymer matrices, or in vitro growth of cells on a matrix. Clearly, none of these
approaches to an artificial ligament is close to the idea of a collagen scaffold.
4.1.5 Bone/Ligament Patents
This search gave many results that overlapped with the previous bone regeneration and
ligament regeneration patent search results. Most of the patents found could be categorized as an
allograft/xenograft, as a protein- or cell-seeded matrix, or as a combination of the two. Most of
the patents found during this search did not actually focus on bone-ligament repair but merely
mentioned bone-ligament repair as a possible application. Further, most of these patents were
aimed toward periodontal applications of bone-ligament repair and did not present a device that
had the proper mechanical properties necessary for an ACL replacement. The search did reveal
one patent that pertained specifically to a bioengineered ACL, and it is reviewed further below.
One patent (US Patent No. 6867247), like the bi-layer bone-ligament scaffold, does not
fall into the allograft/xenograft or living material-seeded matrix category but is very different
from ours. It is mentioned to provide an idea about other approaches being taken to create bone
and ligament scaffolds. The patent describes using polyhydroxyalkanoate polymers for medical
devices and applications, including a bone marrow scaffold and a ligament graft. The premise
behind these devices is that polyhydroxyalkanote polymers have good mechanical properties, are
biodegradable, and have controllable degradation rates.
US Patent No. 6287340: Bioengineered Anterior Cruciate Ligament
This patent describes an ACL that is engineered ex vivo via pluripotent cells. The
engineered ligament consists of a cell-seeded matrix secured between two cylindrically-shaped
anchors. The cell-seeded matrix is composed of type-I collagen in a specific concentration that
may or may not be crosslinked. The anchors are composed of either demineralized bone or
Goinopra coral. The Goinopra coral has pore sizes of 500 gms and has been treated to convert
the calcium carbonate into CaP. To create an ACL that has the same mechanical properties as a
natural ACL, during growth, the synthetic ACL is subjected to mechanical forces which mimic
the forces experienced by a natural ACL. Many of the patent's claims describe the mechanical
forces that will be applied to the ligament.
This claim definitely fits into the category of cell-seeded matrix scaffolds, which makes it
significantly different from our scaffold and rendering it harmless in regards to the patent we are
seeking. However, the structure of this scaffold is noteworthy and similar to ours. The patent
describes three sections to the ligament, two of which are hard tissue acting as bone anchors and
a soft tissue section acting as the ligament itself, which is the same structure as our scaffold. The
bone anchors are composed primarily of CaP whereas the ligament is composed primarily of
collagen, which is very similar to our scaffold, except that in ours collagen is used throughout all
three sections. This patent again shows that the use of collagen and CaP to successfully mimic
the body's natural structures not novel, but the manner in which they are used may be.
4.1.6 Bone/Cartilage Patents
This patent search also came up with many patents that had already been found with the
previous searches. Those that had not been previously found generally fell into the category of
using a living material-seeded matrix. One noteworthy patent was found and is described below.
US Patent No. 6752834: Membrane for In Guided Tissue Regeneration
This patent describes a resorpable multi-layer membrane applicable primarily to bone and
cartilage reconstruction. The membrane has a matrix layer and a barrier layer. The matrix layer
contacts the injured tissue and is composed of type-II collagen with a porous structure, while the
barrier layer faces away from the injured tissue to prevent ingrowth of unwanted tissue and is
composed primarily of type-I collagen, type-III collagen, or a mixture. The layers will be
adhered to each other while in a slurry form to ensure a firm connection between the layers.
Specifically, the matrix layer in slurry form would be applied to an impenetrable, solid barrier
layer and then freeze-dried to form the porous structure.
Clearly, the processing techniques described in this patent are very similar to the ones
used in our process. This is the first patent found that specifically cites the use of a slurry and
the process of freeze-drying to enhance the bond between two layers, which is one of the integral
features to our scaffold, and again indicates that the specific processing techniques and reasons
for choosing them are not unique. However, the combination of multiple techniques and the
exact specifics of the processing should separate our process from existing processes. In contrast
to this particular patent, our scaffold also heavily relies on the precipitation of CaP to strengthen
the scaffold.
4.2 Patent Situation for this Technology
Recent research leading to the specific development of this process was funded by the
Cambridge-MIT Institute (CMI), which is in turn funded by the British government. Therefore,
any company started from this research must be located within the United Kingdom (UK). One
such company, OrthoMimetics Limited, was formed in 2005. For this reason and also because of
the potential over-seas market, all patents (See Table 9) have been filed under the Patent
Cooperation Treaty (PCT) after initial filing in the UK. By filing under the PCT, these patents
are valid in all 132 participating countries, including the US, the UK, almost all other countries
in the European Union (EU), and Japan, which almost completely covers all locations where our
product may be sold.
International Patent PCT/GB2004/004550 PCT/GB2006/000797
Application Number
International Filing Date October 28, 2004 March 7, 2006
Title Composite biomaterials Biomaterial (the
comprising calcium European Patent
phosphate materials, Office will specify a
collagen and more detailed title
glycosaminoglycans upon examination)
Month 31 14
International Publication WO 2005/051477 N/A
Number
International Publication September 6, 2005 N/A
Date
Ownership Cambridge University 50:50 Cambridge
University:MIT
Priority From UK Patent GB 0325161.8, filed GB 0504673.5, filed
Application October 28, 2003 March 7, 2005
Table 9. Status of Patents Concerning the Bi-Layer Bone-Ligament Scaffold.
Another consequence of funding coming from the CMI is that actual ownership of these patents
belongs to MIT and Cambridge University. OrthoMimetics has made a licensing agreement with
CMI through which OrthoMimetics holds an exclusive worldwide license for all relevant fields
of application for both of these patents. Terms of the licensing agreement between
OrthoMimetics and CMI can be found in Appendix D.
Chapter 5. Business Model
The processing method described in Chapter 2 can be used in any application where hard-
tissue, such as bone, is interfacing with a soft-tissue. Soft-tissue includes cartilage, tendons, and
ligaments. ACL replacement is the potential marketplace for the bone-soft tissue scaffold
explored within this business model. After an analysis and comparison of the current solutions
to treating ACL tears and our bi-layer bone-ligament scaffold, two possible products were
identified. The first would be a scaffold for direct replacement of the ACL. The second would
be a scaffold for to be used at the donor site during patellar tendon ACL replacement surgeries.
The technology's application to replacement of degraded joint cartilage due to osteoporosis and
osteoarthritis had already been explored and a company, OrthoMimetics Limited, had been
formed. After the ACL application had been targeted, it was learned that OrthoMimetics also
had an interest in this area and had done some initial exploration into the market. Further, due to
the fact that OrthoMimetics holds the exclusive worldwide license for the patents necessary for
the creation of either an ACL or patellar tendon graft site scaffold, only OrthoMimetics
themselves or a company sublicensing the patents from OrthoMimetics would be able to use the
technology to create the ACL scaffolds. All work completed during the creation of this business
plan was done in cooperation with OrthoMimetics.
5.1 The Market
The bi-layer bone-ligament scaffold would have two markets: all recipients of ACL
replacement surgeries and recipients of only the patellar tendon ACL replacement surgery (See
Section 5.2). Both markets would include the US, the EU, and Japan. Any business formed
using the technology on which the bone-ligament bi-layer scaffold is based must be located
within the UK, and for this reason Europe is considered a market for this product. As the
medical device controls described in Section 5.6.2 apply only to the EU, the following analysis
only includes those European countries within the EU. The potential size of the American and
Japanese markets forces a consideration of the US and Japan in this market analysis.
A search for the number of ACL surgeries performed per year only turned up results for
the US. The data shows that the number of surgeries is increasing each year (See Table 10).
Using data from the US Census Bureau (See Appendix E), these values were converted into
incidence rates, from which a trendline was created to predict the rate of ACL surgeries in 2010
(See
Figure 25), the year the patellar tendon graft site scaffold is predicted to first enter the market.
Using the assumption that the EU and Japanese ACL surgical rates would be the same as the US
rate and the population numbers within the EU and Japan (See Appendix E), the number of
ACL surgeries was calculated (See Figure 26).
Year Number US Population Rate Per 1000 People
1991 95000t  253,492,503 0.375*
1996 1073001 269,667,391 0.398*
2001 165000T  285,023,886 0.579*
2002 175000' 287,675,526 0.608*
2010 261,766** - 0.847**
Table 10. Number and Rate (per 1000 people) of ACL Surgeries Within the US. tSource: OrthoMimetic, 2006;
ISource: AAOS; *Calculated From US Population; **From Figure 25.
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Figure 25. United States Incident Rate of ACL Surgery (Per 1000 People) by Year, 1991 - 2010.
While no data could be found on the number of ACL surgeries performed within the EU
or Japan, data for the number of inpatient procedures in the EU and the US was found. Though
the data came from different sources they were both classified using the International
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). The ICD-9-CM
code for ACL reconstructive surgery is 81.45. While the US data had numbers just for this
category, the EU data only had numbers for operations on the musco-skeletal system, knee
arthroscopy, and total hip replacement, represented by the ICD-9-CM codes 76 to 84, 80.26 to
80.6, and 81.51, respectively. The rates of these three procedure categories within the EU and
the US were compared for the years 1997 - 2003 (See Appendix F for original data). For all
three procedure categories, the EU rate of incidence is about 1.4 times higher than the US rate
and on average 1.3974 times higher. As all three EU procedure category rates are about 1.4
times higher than the US rate, it is assumed that the EU ACL surgery rate is also about 1.4 times
higher than the US rate. In addition to assuming the same incidence rate as in the US, the
number of ACL surgeries within the EU and Japan was calculated assuming the higher EU
incidence rate. Unfortunately, no data could be found on the number or rate of surgical
procedures performed in Japan. In the end, the US rate was applied to the US and Japan, and the
EU rate was applied to the EU to determine the scaffolds' market sizes. It was decided to use the
US rate for Japan because it provided a lower number of surgeries and it is better to be
conservative in estimating the market size. In 2010, the trendlines estimate 261,000, 549,000,
and 108,000 ACL surgeries within the US, the EU, and Japan, respectively (See Figure 26).
This gives a total market size for the ACL scaffold of 918,000 in 2010.
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Figure 26. Number of ACL Surgeries In the US, the EU, and Japan from 2000 - 2010. The EU and Japanese
trendlines were created using US and EU incidence rates.
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To determine the market size for a scaffold used only in patellar tendon ACL surgery, the
percent of surgeries performed that are patellar tendon surgeries needed to be determined. Table
11 shows these statistics for the US, as reported by four different sources. It was decided to use
the 70% patellar tendon statistic because there were two different sources giving this number and
because it was in the middle of the other estimates. Only one source was found for EU data, and
it reported that 58% of all surgeries were patellar tendon surgeries. This lower rate was also
applied to the Japanese data for a more conservative estimation of the market size. These
estimates result in 182,700, 318,400, and 62,600 patellar tendon ACL surgeries in the US, the
EU, and Japan, respectively, in 2010. This gives a total market size for a patellar tendon graft
site scaffold of 563,700 in 2010.
% patellar tendon % hamstring tendon % other Source
80 15 5 (Stone Foundation)
70 25 5 (OrthoMimetics, 2006)
70 75 5 (Feller, 2005)
60 15 25 (RTI, 2004)
Table 11. Percentage Breakdown of the Different Types of ACL Replacement Surgeries.
Despite the difficulty in finding data for the total number of ACL surgeries per year, data
for the number of inpatient ACL surgeries per year in the US was found (See Figure 27). There
has been a clear decline in the number of inpatient ACL surgeries but it appears to be leveling off.
This is in marked contrast to the trend seen for the number of total ACL surgeries, which is
increasing, and can only mean that the number of outpatient ACL surgeries is increasing
significantly. The increase in the number of outpatient surgeries reflects an increase in
minimally invasive surgeries requiring little recovery time.
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Figure 27. Number of Inpatient Discharges for ICD-9-CM Procedure 81.45, the ACL Surgery Classification Code.
(HCUPnet)
5.2 Our Products
A review of the current methods of ACL replacement was made to determine the best
way to introduce our bi-layer bone-ligament scaffold into the market. There are two types of
surgical operations currently used, autografts and allografts, that replace the torn ACL with a
graft taken from the patient or a cadaver, respectively. The autograft is by far, the most popular,
comprising about 90% of all surgeries (CrossCart, Inc.). Of autografts, there are two main places
from which a replacement ACL is taken, the patellar tendon and the hamstring tendon. An
internal survey of 132 surgeons of the International Society of Arthroscopy, Knee Surgery and
Orthopaedic Sports Medicine, revealed that 70% chose the patellar tendon graft as their
replacement of choice, 25% chose the hamstring tendon, with the other 5% using allografts and
synthetics, which are allowed only in countries outside of the US (Feller, 2005).
The patellar tendon replacement surgery is, by far, the most popular option and is
considered the "gold standard" for ACL replacement. The middle third of the patellar tendon is
usually cut out as a bone-ligament-bone graft, where the bone segments are about eight
millimeters in length. As the patellar ligament and ACL are of similar lengths, no adjustment
needs to be made to the graft. The torn ACL is removed and the graft is positioned to mimic the
original ACL. Screws, either metallic or bio-absorbable, are used to position the graft's bone
segments into the patient's femur and tibia. About six to eight weeks are necessary to allow the
graft bone and the natural bone to start growing into each other. One of the main advantages of
this surgery is the superior mechanical strength of the patellar tendon as compared to the
hamstring tendon. Another advantage is that the ligament and bone are both part of the graft and
do not have to be artificially connected using screws, staples, or other fixation devices. Healing
between the graft's bone segments and natural bone is far more successful and quicker than
healing between ligament and bone, leading to quicker recovery time than for hamstring tendon
grafts. The main disadvantage of this technique is that usually nothing is done to "repair" the
patellar tendon. As two-thirds of the tendon still exists, the bone that was cut out may be filled,
but other than this, nothing is done to help the patellar tendon recover and it does not usually
return to its original condition. This commonly leads to pain in the patella area (especially
during kneeling), an increased risk of patella fracture and osteoarthritis, and difficulties in fully
extending the knee.
The hamstring tendon is actually more than one tendon, of which the two most
commonly used for this surgery are the semitendinosis and gracilis tendons. Either one or both
of these tendons can be used as the graft. If two are removed then they are bundled together and
used for the ACL replacement. The hamstring tendon is significantly longer than the ACL, so a
graft from this tendon requires fixating the tendon directly to the femur and tibia. The main
advantage of this surgery is that there is no risk of patellar pain or injury because the patellar
tendon remains untouched. The disadvantages include a lower strength graft, a longer recovery
time due to the tendon to bone interface, and a possibly noticeable decrease in hamstring strength.
The longer recovery time results from the fact that both ends of the graft are not bone, but soft
tissue, and soft tissue-bone healing takes more time than bone-bone healing, and is one of the
reasons surgeons favor the patellar tendon surgery. A fixation device, such as a screw, is used to
secure the tendon graft to the natural bone. In recent years, these fixation devices have been
improving which has encouraged greater use of the hamstring tendon graft.
In an allograft, an ACL from a cadaver is used as the graft. The main advantage lies in
the fact that no other part of the patient's body will be "injured" to provide the graft. Further,
fewer surgical cuts are necessary, because no cuts are made to remove a graft from the patient,
leading to a shorter surgical time, which can significantly decrease the cost of the surgery. The
disadvantages are that the graft is usually weaker than an ACL from a living person because of
the processing it must go through for preservation and sterilization and the risk of disease
transmission. Due to newer sterilization techniques, this risk is very small but it does still exist.
Another problem with allografts is that it is dependent on the availability of a viable cadaver,
which is usually low. Within the US, synthetic grafts have also been attempted, but all
eventually failed due to creep mechanisms. Currently, there are no synthetic replacements for
the ACL approved for use within the US, but some are available in Europe.
There are three main ACL replacement surgeries performed today, and all of them have
at least one serious disadvantage. Clearly, a new product, such as the proposed bi-layer bone-
ligament scaffold, would not have any of the disadvantages. There would be no donor-site
morbidity, as seen in autografts, and there would be no risk of disease, as there is for allografts.
Further, these scaffolds could be made on demand and would not run out. For this reason, the
ideal product would be a scaffold for direct replacement of the ACL. However, assuming a
successful bone-ligament scaffold was created and it succeeded in clinical trials; it could still be
difficult to convince surgeons to try something new. While the patellar tendon surgery can lead
to pain, it does allow about 90% of its patients to return to the same level of physical activity as
before the injury. Further, there are a number of new products being developed, such as this one,
for ACL replacement (See Section 5.3). It could prove difficult to make our product stand out
above all the other options. Further, in the case of direct ACL replacement, the mechanical
properties of the ligament section of the implant would have to be comparable to that of natural
ligament. While it is clear that remodeling occurs in bone, it is unclear how the body naturally
recovers from an injured ligament or tendon. While there is a small degree of vascularization in
these soft tissues, it is not enough to allow a quick recovery or to allow for a significant
rebuilding process to occur. Both healing and rebuilding processes within the body are
dependent on cells being able to reach the injured site, usually via blood vessels. If there are
only a few blood vessels within the ligament, then only a few cells can reach the injured site, and
little healing and/or rebuilding can occur. This sparse vascularization in the ligaments is likely
the cause of the eventual decrease in mechanical properties seen in all current surgical grafts
(Yahia, 1997). Healing could also occur via the action of mesenchymal stem cells (MSC), which
are found in bone marrow. MSCs are progenitor cells that can generate ligament, tendon, muscle,
cartilage, bone, and fat. It is possible that the bone marrow, and therefore the MSCs, within the
natural human cancellous bone would migrate first into the neighboring bone scaffold and then
into the ligament scaffold. Once within the ligament scaffold, the MSCs could initiate
generation of ligament tissue that would help reinforce the ligament scaffold. At this time, it is
unknown if this would actually happen and if it did how much it would help. In the case of
direct ACL replacement, the ligament section of the ACL scaffold would act more as a
replacement than an actual scaffold due to the unknown but predicted limited ability of the body
to rebuild a new ligament. The increased mechanical property requirements of an actual
replacement would require much further development of the technology and product.
Therefore, it is proposed that, initially, the bi-layer bone-ligament scaffold be targeted
toward the patellar tendon donor site to help healing. Currently, little is done to encourage repair
of the donor site besides using bone cement to replace the bone, and no attempt is made to
account for the section of the ligament that is removed. The scaffold would be placed in the site
from which the graft was taken, leading to improved healing of the tendon, and drastically
reducing the risk of pain, injury, and reduced motion. The scaffold's mechanical properties
requirements in this capacity would be much less as this implant would be both a bone and
ligament scaffold. The bone scaffold would only need to maintain its shape until remodeling
occurred and the scaffold is integrated into the natural structure. It would also need to be shape-
able with a scalpel. The bone sections of the implant would be inserted into the holes left behind
when the bone plugs of the patellar tendon graft were cut out of the tibia and patella. These
holes would differ slightly from surgery to surgery making it necessary that the bone scaffold
could be shaped with a scalpel to ensure a good fit. The ligament scaffold would act as a bridge
between the two remaining sections of the patellar tendon, and hopefully encourage and help any
healing processes that occur. The scaffold would not need to carry much, if any, mechanical
load because of the two remaining and intact sections of the patellar tendon. The use of the
scaffold at this site would not require any fixation devices because after ACL surgery, the patient
must usually remain immobile for a certain amount of time, during which the bone scaffold
would already start to bond to the natural bone. By the time the patient does become mobile the
bone scaffold would be securely bonded to the natural bone, preventing dislodgement of the
implant. Further discussion of the risks of commercializing these two scaffolds can be found in
Section 5.5.
5.3 The Competition
A number of other companies are also currently developing new ACL replacement
devices that would act in direct competition to our bi-layer bone-ligament scaffold. A review of
these companies, their products, and their patents will be given. While this does not cover all the
competitors, it gives a sampling of other available treatment options. It should be noted that
none of these companies appear to be interested in adapting their ACL grafts to be used at the
patellar tendon graft site, meaning the patellar tendon graft site scaffold would have no
competitors.
CrossCart, Inc. has developed a patented process to completely remove any immunogenic
components from animal tissue, allowing for the safe implantation of animal parts into humans.
Specifically, they hope to use this technique to sterilize a porcine-derived bone-patellar tendon-
bone graft and use it as an ACL replacement and have called it Z-Lig. In 2005, the FDA
approved a clinical trial for Z-Lig. The trial compares Z-Lig to allografts and is multi-site and
blinded. Clearly, they are a few steps ahead in the product development stage than we are.
However, they also have many more regulations to meet before their product can be approved for
commercial sale within the US (See Section 5.6). (CrossCart, Inc.)
Tissue Regeneration Inc. has patented a method of seeding adult stem cells on a silk fiber
matrix and directing the differentiation of theses cells into ACL cells. This would allow them to
grow an ACL in vitro and use it as an implant. (Tissue Regeneration Inc., 2004)
Regeneration Technologies Inc. has a number of patents pertaining to the use of allografts
and xenografts and has a trademark method of sterilization, just as CrossCart, Inc. does. They,
unlike the last two companies, do not focus primarily on ACL replacement, but also offer
products for other orthopedic, oral maxillofacial, urinary, and cardiovascular surgeries. For ACL
replacement they offer a number of tendon allografts.
Cryolife, Inc. is a company focused on products that have been cryogenically preserved
for use in cardiovascular and orthopedic applications. For ACL replacement, they offer Achilles
and patellar tendons. In 2002, the Food and Drug Administration (FDA) made Cryolife recall all
its distributed human allograft tissues due to documented fungal and bacterial contamination of
its tissues. At this time, Cryolife has dealt with the problem and continues to sell its products.
It is clear that our bone-ligament scaffold would hold a number of advantages over
current treatment options for ACL tears, but many of the newer products also hold these same
advantages (no donor site morbidity in autografts, short supply of allografts). However, our
bone-ligament scaffold also holds advantages over the other technologies described above. First,
all the products described above fall into one of two categories, (1) allografts and xenografts or
(2) tissue-engineered products. These four companies above do not encompass all the companies
that might have a product that could be in direct competition with our bi-layer bone-ligament
scaffold, but they give a good representation of the general trends in ACL replacement. That is,
most research is being focused on sterilization techniques for allografts and xenografts and on
tissue-engineering with the use of live cells. A great deal of research is being focused on using
cells to either grow tissue in vitro, as is being done by Tissue Regeneration, Inc. or to encourage
the body's natural healing and remodeling processes once implanted within the body. This focus
on using cells is reflected in the patents described above and many other encountered during the
IP search (See Chapter 4) that describe seeding of cells on a scaffold or matrix of some sort. Our
product does not fall into either of these categories, which helps it stand apart from the
competition. In the case of allografts and xenografts, there is still a serious risk of poor
sterilization leading to, at best, implant rejection and, at worse, infection, disease, and/or death.
Even a large company such as Cryolife was a victim of this as the FDA recall of its products
stemmed from the death of a person receiving an implant for reconstructive knee surgery (Online
Lawyer Service, 2004). Previous incidents such as these may make it difficult to convince
patients and surgeons to use this type of replacement. Within the US, the FDA is in charge of
approving drugs, devices, and biological products before they can be sold (See Section 5.6.1).
Both the allografts/xenografts and tissue-engineering products are considered biological products,
which must go through a far more stringent approval process, requiring more time and money,
before they can be put on the market. Our bone-ligament scaffold, on the other hand, is
considered a device. This essentially means that our product will take less time to reach the
market than these other early-stage competing technologies. If our product can establish itself in
the marketplace before other competing products even reach the market, this could be a large
enough edge to sustain us. Furthermore, any competing products involving the use of
embedding cells or drugs to encourage healing could be used with our product. If our product
hits the marketplace first and establishes itself, then any technologies requiring a delivery system
could be incorporated into our product and would no longer be competition but a possible
enhancement. Another advantage of our product would be that it could, theoretically, be tailored
for every specific patient. A person's body is unique and if the scaffold could be designed
specifically for a person, this could increase the rate and extent of healing that occurs. By
designing a specific scaffold, it is meant that the size and strength of the scaffold could be made
on a person-to-person basis. Further, depending on the injury itself (location, extent, etc.), a
scaffold with certain mechanical properties could be desired. This type of personalization is
possible due to the relatively low number of units that would be made. Competitive products
based on allografts and xenografts would be limited to what was available. It would be difficult
to find the "perfect" graft if anything special was needed.
5.4 Possible Business Model Options
There are three obvious business models that could be used in this situation:
* Sell the patents and ideas for the scaffold as soon as possible,
* Use the patented technology to produce the scaffolds in-house, and
* Use the patented technology to produce the scaffolds but out-source the actual
manufacturing.
For the last two scenarios, the exit strategy would be to eventually sell the company. As noted
earlier, this research has been funded by the Cambridge-MIT Institute (CMI). All of the work
completed within the last four years has been part of a £2.0 million project. This funding
reduced the risk of exploring the technology to almost nothing and enabled development of the
technology and creation of a preliminary bone-ligament scaffold. Until recently, no venture
capitalist or similar entity had financed the project in any way, meaning, currently, there is no
rush to pay back investors. Further, at this point, the risk for a potential buyer is still pretty high
because a significant amount of development still needs to be completed before a sellable
product is made. Therefore, the first option does not seem to be practical or likely to happen.
With the last two options, the company could be sold at any point. As the company moves closer
and closer to making a sellable product, the risk for a potential buyer decreases, hopefully
leading to significant buy-out offers. Due to the time necessary to set up a manufacturing facility
that meets all quality standards, the difficulties in increasing production if demand for the
product is high, and the difficulty of transfer in the case of an acquisition make out-sourced
manufacturing the better option (OrthoMimetics, 2006). Even if this option is pursued, it is
important to keep in mind the eventual exit strategy: selling to a large medical-technology
company. Everything that is done before this point should improve the company's value for the
potential buyer.
5.5 Risks
The risks in starting a company based on the commercial application of the bi-layer bone-
ligament scaffold to ACL replacement can be divided into two categories: technical and
business. The technical risk is the probability that the necessary mechanical properties can be
obtained and the business risk is the probability of convincing surgeons to use the product. At
this time, there is an obvious risk of failure at any time along the development road. While we
have the basic technology to produce a bone-ligament scaffold, there is still work to be done to
create a product with the necessary mechanical properties. At this time, there is a lot of
confidence that the scaffold's mechanical properties can be improved enough to create a working
scaffold for the patellar tendon graft site. However, the work needed to create a working
scaffold for direct ACL replacement is much greater and the possibility of failure is much greater.
The different mechanical properties requirements were discussed in Section 5.2.
Even if a scaffold with the necessary mechanical properties for either the patellar tendon
graft site or direct ACL replacement were created, commercial success is dependent on
convincing surgeons to use our products. Convincing surgeons to use the scaffold at the patellar
tendon graft site should be relatively simple. Inserting the scaffold into the graft site would take
relatively little time and would not require any further instruments as fixation devices are not
necessary (See Section 5.2). For the surgeon, it would be a relatively simple procedure of taking
the graft, carving the bone scaffolds into the right size, and inserting it. Further, there is little
risk that the scaffold would result in other problems, and if it does, it will be discovered during
prior clinical trials. On the other hand, there is a great potential benefit of eliminating donor site
pain resulting in happier and more satisfied patients. Due to the potential benefits, the ease of
implantation, and the lack of alternatives, there is little risk that surgeons will refuse to use the
scaffold at the patellar tendon graft site if the necessary mechanical property requirements are
obtained. The task of convincing surgeons to use the scaffold for direct ACL replacement will
be significantly harder. Even if the scaffold is proven effective through clinical trials, surgeons
might also want to know that it holds advantages over current options before using it because the
current options do provide satisfactory results. Further, clinical trials would be able to show its
initial effectiveness, but not its long-term effectiveness. However, the main difficulty will just
be trying to convince surgeons who have been using the current options for a number of years to
try something new and completely different.
The patellar tendon graft site scaffold would seem to pose little risk, both technically and
business-wise, whereas the direct ACL replacement scaffold poses a high degree of risk in both
areas. This would indicate that the probability of commercial success is much higher for the
patellar tendon graft site scaffold. This indicates that the strategy of initially focusing on
producing and marketing the graft site scaffold is a good one, and that focusing on an ACL
scaffold only would probably not be successful. However, if the graft site scaffold takes off,
then the profits gained could be used to further develop the scaffold for a direct ACL
replacement. In this case, the risks of exploring the ACL scaffold would decrease significantly
because success of the graft site scaffold could prompt surgeons to use the ACL scaffold and
only profits would be used for development.
5.6 Device Regulatory Procedures
Each of the three different geographic markets, the US, the EU, and Japan, have different
regulatory procedures before a product such as the bone-ligament bi-layer scaffold can be put on
the market. Knowledge of these procedures is necessary to make an informed decision about
how each product should be sold and distributed in the three markets and to make an estimation
of the product timeline within each market.
5.6.1 The United States
Within the US, the government agency that would concern us would be the Food and
Drug Administration (FDA), whose mission statement is as follows:
"The FDA is responsible for protecting the public health by assuring the safety, efficacy, and
security of human and veterinary drugs, biological products, medical devices, our nation's food
supply, cosmetics, and products that emit radiation. The FDA is also responsible for advancing the
public health by helping to speed innovations that make medicines and foods more effective, safer,
and more affordable; and helping the public get the accurate, science-based information they need
to use medicines and foods to improve their health." (FDA)
Of the eight product categories the FDA regulates (drugs, biologics, medical devices, food,
cosmetics, products that emit radiation, animal feed and drugs, and combination products) the
bone-ligament bi-layer scaffold would fall into either the biologics or medical device category.
The components of our scaffold that might place it into the category of a biologic would be the
bovine collagen or the GAG. The FDA says that a biologic includes "live animal cells, tissue, or
organs" from another animal or human tissue, such as "skin, tendons, ligaments, and cartilage."
Neither the collagen nor GAG used in our scaffold can be considered live and so does not fall
into the category of a biologic device. This is a good thing because approval of a biologic takes
much longer due to the requirement of three specific phases of clinical testing. The
categorization of our scaffold as a device as opposed to a biologic already gives us an edge over
any competitors interested in using an allograft, a xenograft, or a matrix seeded with living cells,
because of all these are considered biologics and it will take them longer to have their product
approved for sale on the open market. Our product will reach the market first, allowing it to
carve out a share of the marketplace while the competition is still trying to obtain FDA approval.
The division of the FDA dealing specifically with medical devices is the Centre for
Devices and Radiological Health (CDRH). In 1976, through the Medical Device Amendment,
the FDA established three classes of medical devices. These classes, among other things,
determine what type of premarketing submission/application is required before the FDA deems a
product safe and effective for market. Devices are placed in the different classes based on risk
the device poses to the patient and intended use. Class I devices pose the least amount of risk,
include such items as elastic bandages and examination gloves, and are subject to the regulations
referred to as "General Controls", to which all devices are subject. Class II devices pose a
medium risk to the patient, include powered wheelchairs and infusion pumps, and, in addition to
meeting the general control requirements may also be subject to special controls, such as special
labeling requirements, mandatory performance standards, or postmarket surveillance. Class III
devices usually support or sustain human life, are of importance in preventing impairment of
human health, or present an unreasonable risk of illness or injury. They include implantable
pacemaker pulse generators and endosseous implants and must go through the additional process
of premarket approval. Submission of a 510(k) Premarket Notification is required for all three
device classes. A premarket notification must be submitted at least ninety days before the device
is introduced to the market and notifies the FDA of the intention to sell the device on the market.
The FDA uses this notification to determine if the product is "substantially equivalent" to an
already-approved safe and effective device or if it is different how the differences will affect the
device's safety and effectiveness. A premarket approval (PMA) is required of all Class III
devices. The reason a PMA is also required of a Class III device is because there is not enough
information about these devices to ensure safety and effectiveness solely through general and
special controls. PMA documentation should demonstrate the safety and effectiveness of the
Class III device through a non-clinical laboratory and a clinical section. The non-clinical
laboratory section should include information on microbiology, toxicology, immunology,
biocompatibility, stress, wear, shelf life, and other laboratory or animal tests. The clinical
section should include study protocols, safety and effectiveness data, patient information, patient
complaints, tabulations of data from all individual subjects, results of statistical analysis, and any
other information from the clinical investigation. Once the PMA documentation has been
submitted, the FDA has 180 days to review the information and either accept or reject it.
Usually, the review time is much longer because the FDA will request or the owner will wish to
supply supplemental and amended information. Once the FDA makes a decision, interested
parties have 30 days to appeal the decision. Before obtaining approval, the applicant must also
undergo a successful FDA inspection of the proposed manufacturing site, during which time, the
FDA will determine if the manufacturer has an established quality control system. (FDA;
OrthoMimetics, 2006)
It is believed a bi-layer bone-ligament scaffold will be considered a Class III device for a
number of reasons. First, similar existing devices, such as synthetic ligaments and tendons are
considered Class III devices. The technology behind the scaffold will be new and could not be
compared for substantial equivalence to an existing device. The surgery required for
implantation of the scaffold poses the risk of serious injury to the patient, a major classifying
factor as identified by the FDA. The use of animal part derivative might also be sufficient reason
for a Class III classification. Further, endosseous implants, those where part of the implant is
embedded in bone, are usually classified as Class III devices and our scaffolds would fit into this
category.
5.6.2 The European Union
Within Europe, the European Commision (EC) has established three directives which
outline the regulations of marketing medical devices and putting them into service. The directive
which the bone-ligament bi-layer scaffold would be subject to is the Medical Devices Directive
(MDD), officially known as Directive 93/42/EEC. The MDD defines four classes, Class I, Class
IIa, Class IIb, and Class III, into which all devices are placed, with Class III devices holding the
highest risk to the patient. Classification depends on a variety of factors, including the length of
the device's intended use, whether or not the device is invasive, whether or not the device is
implantable, and whether or not the device contains a substance which on its own could be
considered a medicinal substance. Using the guidance document "Guideline for the
Classification of Medical Devices" issued by the EC, it is clear that the bone-ligament bi-layer
scaffold would be classified as a Class III device. Rule 8 of the document states that "all
implantable devices...are in Class IIb unless they are intended: to have a biological effect or be
wholly or mainly absorbed, in which case they are in Class III," (EC, 2001). Further, Rule 17
says "all devices manufactured utilizing animal tissues or derivatives rendered non-viable are
Class III," (EC, 2001). A schematic of the conformity assessment routes for Class III devices is
shown in Figure 28.
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Figure 28. Schematic Map of Conformity Assessment Route for Class III Medical Devices. (Taken From EC, 2001)
The end result of the conformity assessment is CE Marking, which allows a product to be
freely distributed throughout the EU and European Free Trade Association territories. For Class
III devices, there are two ways in which CE Marking can be obtained. The first route is under
Annex II, which requires the assessment of the manufacturer's quality system for the design,
manufacture, and final inspection of the product and must submit to a design dossier examination
by a notified body (NB). A NB is a certification organization which the national authority of a
member of the European Union designates to carry out one or more of the conformity assessment
procedures described in the directives. The quality system should meet the regulations outlined
in the International Organization for Standardization's standard ISO 13485:2003, which
"specifies requirements for a quality management system where an organization needs to
demonstrate its ability to provide medical devices and related services that consistently meet
customer requirements and regulatory requirements applicable to medical devices and related
services," (ISO, 2003). The second route is through Annex III/Annex IV or Annex III/Annex V
approval. Annex III requires a type examination by a NB, where a type examination is one in
which it is demonstrated that the device design meets the relevant essential requirements of the
MDD. Annex IV requires that every produced device meets essential requirements of the MDD
as determined by a NB. Annex V requires that the manufacturer establish a quality system for
the manufacture and inspection of the produced device that is approved by a NB. The main
difference between the American and European regulations is that the European regulations
require that a product only be proven safe, not effective. Therefore, less testing is required and
medical device approval can be obtained in less time in the EU than the US.
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5.6.3 Japan
In Japan, medical device regulation falls under the control of the Ministry of Health,
Labor, and Welfare. Since April 2005, a revised Pharmaceutical Affairs Law (PAL) has changed
the way foreign medical device manufacturers are dealt with inside Japan and has resulted in the
establishment of the Pharmaceutical and Medical Device Agency (PMDA). With this new
system production can only be performed by a manufacturer, while full authority over product
release and sale of the device is given to a Marketing Authorization Holder. Like the US and the
EU, Japan categorizes medical devices into classes based on potential risk to the patient. Under
the revised PAL, Japan now uses three classes (instead of four): ippan iryo kiki, kanri iryo kiki,
and kodo-kanri iryo kiki. Devices falling into the kodo-kanri iryo kiki category correspond to
devices that fell previously into Class III and Class IV and are referred to as specially controlled
medical devices. Under the old system, the bone-ligament bi-layer scaffold would likely have
been considered a Class III or Class IV, so under the new system it will fall into the kodo-kanri
iryo kiki category. These devices require product approval from the PMDA, which follows after
submission of a product application and Summary Technical Documentation (STED). STED
documents include those describing the product development process, product information, raw
materials, storage methods, manufacturing process information, verification and validation data,
risk analysis data, and labeling information. PMDA product review can take 12 months and cost
$63,000 (Gross b, 2005). A Japanese company that wants to market a foreign medical device
will need to obtain a license for manufacturing/marketing business; depending on the category
that device falls into a certain license type will be required. For specially controlled medical
devices, such as our scaffold, a License Type No. 1 will be required. The company holding this
license is called the Marketing Authorization Holder (MAH), and must be located within Japan.
For each product the MAH wishes to market they must obtain marketing approval (hanbai
shonin) by guaranteeing the quality, safety, and efficacy of the product, and ensure compliance
with other requirements such as Good Manufacturing Practices (GMPs) for the manufacturing
establishment, the production control system, and the quality control system. The MAH must
have three controllers, based in Japan, referred to as a general controller, a quality assurance
controller, and a post-marketing safety management controller. The general controller will
supervise all MAH duties. The quality assurance controller ensures that the MAH is complying
with Good Quality Practices (GQPs) that govern product quality. The post-marketing safety
management controller will be in charge of Good Vigilance Practices (GVPs), which give
guidance on monitoring post-market sales in the market and on taking immediate action to
minimize any public health hazards.
A foreign manufacturer lacking a Japanese subsidiary or office will need to designate an
MAH when applying for product approval. The Designated MAH (D-MAH) will assume all the
responsibilities that the MAH had and is usually the Japanese importer/distributor of the medical
device, but may also be a third-party. Even if a foreign company receives this type of product
approval, only the D-MAH can import and market the approved foreign devices. Foreign
companies without a subsidiary or office in Japan can either ask their importer/distributor to
obtain the marketing approval (hanbai shonin) in the name of the importer/distributer, in which
case the importer/distributor has complete marketing control of the products in Japan or they can
obtain the marketing approval in their own name by designating their importer/distributor as a D-
MAH.
5.7 Product Distribution
As we plan to sell our products over the world, product distribution is an important topic.
Our products need to be delivered on time and depending on the geographic market certain
approaches may prove more successful than others. There are three ways in which we could
deliver our product:
* Sell directly to the customers,
* Partner with niche/specialized distributors, or
* Partner with large medical-technology companies.
There are a number of factors governing which of these options should be chosen. Two of the
most important ones are revenue retention and market penetration rate. If the company were to
sell directly to the customers, all of the revenue would be retained, but if the company were to
partner with a large medical-technology provider, much less of the revenue would be retained.
Partnering with a niche distributor would lead to revenue retention between the other two options.
Market penetration rate depends on, among other things, a large presence and a good reputation
within the market. Market penetration would be greatest if the company were to partner with a
large medical-technology provider and least if it were sold directly to surgeons. Other factors
include control of the marketing strategy, operating room presence, and cost of set-up. As with
the other factors, selling directly to our customers and partnering with a large medical-
technology company would represent the extremes and partnering with a niche/specialized
distributor would lie somewhere in the middle. Partnering with a niche/specialized distributor
would probably be the best choice if only these factors are considered. (OrthoMimetics, 2006)
In addition to these general factors, the culture, medical device regulations, normal device
distribution practice, and proximity of the region to which the product is being distributed are
also a consideration. These characteristics of the three main geographical markets for the
scaffold, the US, the EU, and Japan, will be considered to arrive at the best choice for product
distribution.
Besides the fact that the correct choice of product distribution could greatly affect the
eventual commercial success of the company's products, it is also important because it will
affect the company's value in the eyes of potential buyers. The presumed buyers of the company
will be large medical-technology companies. If distribution deals to the three geographic regions
are established before the company is bought, the company's value lies not only in the
technology and products but also in the markets it has already secured. For example, if the
company were to partner with a large medical-technology company within the US, this company
may eventually turn out to be the company that will want to buy the company. If our company
also partners with this company to distribute within Europe and Japan as well, our company is
basically under their control already. If they wanted to buy us out, there would be nothing our
company has to offer that the company doesn't already have. However, if we were to partner
with different companies in Europe and Japan then when the large US medical-technology
company wanted to buy us out, we would also have established market entry points into Europe
and Japan for them. Partnering with different companies in the three geographical markets
would be the optimal outcome to increase the company's value to a potential buyer.
5.7.1 US
The medical device regulations (See Section 5.6) for a foreign product do not appear to
be any different than for an American product, and are clearly defined by the FDA. Further,
most of the testing required by the FDA to prove the device is safe and effective would be
conducted by the company before selling the product anyway. Relationships are good enough
between the US and England that there would be no cultural hesitance to using an English
company's product. Still though, the US would be a large foreign market. The easiest product
and most commonly used distribution route would probably be through a large medical-
technology company that already has an established market within the US.
5.7.2 Europe
Europe would likely be the easiest market to pursue in terms of proximity and cultural
acceptance. The testing needed to meet the EC medical device regulations would likely be the
same as those needed to meet the FDA medical device regulation. All three product distribution
routes are viable for this market, so finding a niche/specialized distributor would probably be the
best choice.
5.7.3 Japan
In Japan, the implementation of the MAH system already provides a number of
roadblocks to a small foreign business, as ours would be. This business would have no office or
subsidiary located in Japan, forcing it to find a D-MAH. A small company that designates their
importer/distributor as their DMAH must put the company's confidential information, in regards
to product development and raw materials, at risk since the D-MAH, the distributor in this case,
must have access to this information. If the company should ever wish to change distributors
this could be difficult since the distributor and D-MAH are one and the same. The distributor
may try to threaten to use its knowledge of the company's confidential product information to
prevent the company from changing distributors. Financially, any monthly fees the D-MAH
might incur will usually be covered if the distributor and D-MAH are the same because the
distributor will expect the profit margin's of the product to cover these fees. If a small company
uses a third-party D-MAH, not the distributor, they will be subject to fees to cover the D-MAH
expenses. D-MAH expenses will include the services and requirements of GQP and GVP, D-
MAH personnel, and adverse effect reporting. The third-party D-MAH usually charges a flat
rate between $5,000 to $8,000 or will charge a smaller monthly retainer ($3,000 to $4,000) plus a
percentage of the product sales in Japan (Gross, 2005). On the other hand, this third party will
have a greater incentive to keep the company's information confidential to uphold their
reputation. Also, changing distributors should be easier. Considering mainly the issue of D-
MAH monthly fees, it has been suggested that companies with sales of less than $500,000 per
year in Japan should use a distributor as their D-MAH, companies with sales between $500,000
and $2 million per year should obtain a third-party D-MAH to protect their confidential
information, and companies with sales over $2 million per year should consider setting up an
office to act as their own MAH (Gross, 2005). The Japanese medical device regulations alone
act as a significant barrier to entering the Japanese market.
Another important factor to consider is the cultural differences between Japan and Europe.
Japanese people have a strong cultural identity and may be reluctant to use a European product.
It would appear that given the difficult medical device regulations and the possible cultural clash
that none of the product distribution methods mentioned before would be successful. Another
option would be to create a licensing deal with a Japanese company where we would share the
technology and manufacturing process with them in return for an upfront payment and royalties.
In this case, the Japanese company would have to deal with the medical device regulations,
which would be simpler than for a foreign company, and they would know better how to modify
or market the technology within the Japanese culture.
5.7.4 Distribution Strategy Example
It seems likely that, in some way, an alliance or partnership with a large medical-
technology company will be formed; either for product distribution, to sell the company to, or
both. This has become a common strategy for new biotechnology firms, and should not be
difficult to do (Feldman, 2001; Wharton, 2004; Mudhar, 2006). The difficulty for a small
company such as ours will lie in partnering with the firm that will give us the best deal and not
being taken advantage of. To avoid this, many alliances are made through an intermediary, such
as venture capitalists, lawyers, and accountants, who know a lot about the industry and the large
companies within the industry. Even if an intermediary is used, knowledge of the general terms
of previous alliances and partnerships within the industry will be useful. Specifically, the
average percent of sales revenue producers give up to distributors would prove to be a useful
number to have when creating a distributing deal of our own. However, these numbers are rarely
released publicly making them hard to find. Instead a look at the distribution strategy of another
small biotechnology company will be reviewed with as much detail given about the individual
alliances as could be found.
Bioniche Pharma Group Limited (BioNiche Pharma) sells the product Suplasyn®, a
hyaluronic-acid based product used for the treatment of osteoporosis, especially at the knee.
While this is a significantly different product from our scaffolds in terms of how it is
administered (injection versus surgical implant), what it is (liquid versus solid), and what it treats
(osteoarthritis versus torn ACL), it is similar in that both are considered orthopaedic products
and both are meant for treatment of knee injuries. For these reasons, it was thought that
BioNiche Pharma's distribution methods of Suplasyn® could be instructive. Another similarity
is the location of the manufacturing plants: BioNiche Pharma's is located in Ireland and our
company's would probably be located within England. Currently Suplasyn® is being distributed
to 30 countries in the Americas, Europe, and Asia. Within the Americas, they do not sell to the
US but they do sell to Canada. While Canada's population is much lower than the US's, its size
and location are comparable to the US. In Canada, BioNiche Pharma has formed an alliance
with Stryker Canada, a part of Stryker, an international distributor of all types of medical
equipments with a focus on orthopaedic implants. Stryker has annual sales of $4.9 billion
worldwide, of which 82% comes from their Orthopaedics Implant and Equipment sector.
Stryker would be considered a large medical-technology company. Within Europe, BioNiche
Pharma has formed alliances with a number of different companies (See Table 12).
Distributor Countries
Sanova Pharma Austria
Vocate Pharmaceutical S.A. CyprusGreece
Czech Republic
PolandGriinenthal Group RussiaRussia
Slovak Republic
IPC-Nordic A/S Denmark
Chiesi Farmaceutici ApS France
Merckle-Recordati Germany
Premier Medical Limited Ireland
Laboratorios Rubi6 Spain
RobaPharm AG Switzerland
Pliva Pharma Group United Kingdom
Table 12. Distributors BioNiche has Formed Alliances With to Distribute Suplasyn®. (Suplasyn)
While these companies range in size, it is noteworthy that BioNiche Pharma did not
choose to partner with a large international firm like Stryker to distribute Suplasyn@ in Europe.
Instead, it chose to use niche distributors who only have a large presence in specific countries.
BioNiche Pharma does not sell Suplasyn® in Japan, but as in Europe, they have developed
individual alliances with niche distributors for the Asian countries they do distribute to. No
information on the details of these individual agreements could be found. In 2006, BioNiche
Pharma Group Limited was sold by BioNiche Life Sciences Inc. (BioNiche LS) to RoundTable
Healthcare. The terms of the agreement are as follows:
* $13.25 million up-front, prior to transaction-related expenses, to BioNiche LS;
* Annual royalty payments to BioNiche LS of up to 1.0 million for each of the
next five years related to Suplasyn® sales, providing certain sales targets are met;
* Up to $11.5 million in aggregate performance payments for each of the next four
years providing certain business performance targets are met; and
* 10% ownership of the new BioNiche Pharma group (BioNiche, 2006).
The total monetary value of this agreement to BioNiche LC stands to be approximately $33
million. While the terms of the sale were not based solely on Suplasyn@, as it is the only
product mentioned by name in the agreement, it would appear that Suplasyn® is BioNiche
Pharma's main product. While no definite conclusions can be made, one can assume the
distribution deals BioNiche Pharma had already established for Suplasyn® before the sale helped
increase its overall value. A company that was not one of the distributing partners bought the
BioNiche Pharma, and it is unlikely this would have happened if a single company, such as
Stryker, were in charge of distribution all over the world.
5.8 Pricing Strategy
In the case of the patellar tendon scaffold, there is no comparable product currently on the
market, so a price based on competition can not be made. The price shouldn't be too high as this
scaffold would not be used at the primary injury site, the ACL. It was found that in a total joint
replacement, bone-graft substitute material accounts for 6-10% of the total cost of the surgery.
As the bone-graft substitute material is also used as a way to fix a secondary injury site it was
decided that this was a reasonable product to use as comparison. The total price of an ACL
replacement surgery within the US is about $10,000, leading to a patellar tendon scaffold price
ranging from $600 to $1,000 (6 - 10% of $10,000).
The ACL scaffold will be used at the primary injury site, meaning it could be priced
higher. The comparison of the ACL scaffold to an allograft is a good one in that the benefits of
reduced surgical time and fewer surgical cuts needed as compared to an autograft surgery are
similar. A search into the price of US ACL surgery costs, specifically allograft surgery costs,
within the US, the breakdown of these costs, and the cost of the graft used in an allograft surgery
yielded little results. The search led to only three useable sources of information: (1) a Baylor
University Medical Center financial analysis of ACL reconstruction, (2) a Boston University
orthopaedic surgeon practicing at the Boston Medical Center, and (3) the Healthcare Cost and
Utilization Project (HCUP). The Boston University orthopaedic surgeon, Dr. William Creevy,
was reached via email. Dr. Creevy provided ACL surgery hospital charge data (See Appendix
G) for surgeons practicing within his group and was also able to provide other information. He
said that most of the data was for allograft surgeries, but could not identify which ones. HCUP is
a group of databases including the Nationwide Inservice Sample (NIS) which has information on
hospital inpatient stays.
The surgical cost to the patient includes the surgeon's fee, the anesthesiologist's fee, and
the hospital charge. The hospital charge likely includes an operating room cost, a preoperative
charge, a recovery room fee, and a daily fee if the patient spends more than 23 hours in the
hospital (Bonsell, 2000). For an allograft surgery, the cost of the allograft may or may not be
included in the hospital charge. Despite the differences in the data, which will be discussed later,
they are all for hospital charges only, and exclude the surgeon's and anesthesiologist's fee. The
three sources of data for the average hospital charge (see Table 13) give values ranging from
$6,000 to $13,000. The data from HCUP shows how the charge has increased from 1993 - 2003
for inpatient ACL surgeries. An inpatient surgery is one in which the patient stays in the hospital
for a day or more after surgery whereas an outpatient surgery is one in which the patient will
leave a few hours after the surgery is completed. For this reason, inpatient hospital charges are
likely to be higher than outpatient hospital charges as the patient will be occupying a bed longer.
The status of the BMC data points is unknown, the Baylor data can be divided into stays greater
than one day (inpatient), overnight admissions, and outpatient surgeries, and the HCUP data is
only for inpatient surgeries. Another cause of charge differences may be the year from which the
data was collected. The HCUP data clearly shows that the cost of inpatient hospital charges has
increased throughout the years (See Figure 29). The Baylor data is from surgeries within June
1995 to October 1999, whereas the BMC data is more recent, but the exact timeframe is
unknown. Taking this into account, the average cost of inpatient ACL surgery from 1995 - 1999
calculated from the HCUP data was $10,046, which is comparable to the Baylor University
hospital charge for patients staying more than one day, $9,056. The BMC data is probably from
within the past couple of years, but the BMC average hospital charge is less than the HCUP
average for 2003 and comparable to HCUP data from 1999 and 2000. However, the BMC data
probably includes both inpatient and outpatient data, instead of just inpatient data, which would
result in a lower average cost. Despite the large range in values and the differences in source, the
data do, in general, seem to support each other and provide an idea of the cost of ACL surgery
within the US. It should be stated again, that this data represents only the hospital charges, and
does not include the surgeon's fee or the anesthesiologist's fee. Dr. Creevy said that within his
group the surgeon fee was $1,500. One can assume that the anesthesiologist fee is comparable to
this, which increases the average ACL surgery cost by $3,000.
HCUPBMC Baylor University
(Creevy, 2006) (Bonsell, 2000) (HCUPnet)
Year Hospital Charge
$13175 Outpatient $6822 1993 $8,834
Overnight $7692 1994 $8,941
admission
> 1 day $9056 1995 $8,830
All $7352 1996 $9,239
1997 $10,104
1998 $11,061
1999 $12,644
2000 $14,306
2001 $15,787
2002 $16,857
2003 $24,843
Table 13. Average Hospital Charge for ACL Surgery From Three Different Sources.
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Figure 29. Average Hospital Charge for Inpatient ACL Surgeries, from 1993 to 2003. (HCUPnet)
While the data described above is relevant, it is not particularly useful because it does not
help to identify the cost of allograft surgeries as compared to autograft surgeries nor does it
provide any information on the cost of the allografts themselves. Unfortunately, no "official"
numbers for this value were found; however, Dr. Creevy estimated the cost of an allograft,
usually a posterior tibial tendon for his group's surgeries, to be about $900, and that this fee was
included in the hospital charges data he was able to provide. If it assumed that all the surgeries
included in the data Dr. Creevy provided were inpatient surgeries, then a $900 allograft would
account for, on average, 7% of the total hospital charge, and about 5.5% of the total cost of the
surgery (hospital charge plus $3,000 for the surgeon's and anesthesiologist's fees). If this is true,
then a reasonable price for the ACL scaffold would also be about $900, which would be about
the same price as the patellar tendon scaffold, which would seem to be too low of a price. On the
other hand, one can assume that the cost of an allograft surgery is cheaper as compared to an
autograft surgery due to the decreased operating time, and that an allograft costing $900
constitutes a larger percentage of the total cost of the surgery (Bonsell, 2000). It should be kept
in mind that this allograft cost of $900 is not official, it is merely an estimate given by a single
individual who is not responsible for buying the graft. The actual price of an allograft may be
significantly different. However, at this time, as no other data has been found, a good place to
start for the price of the ACL scaffold would be $900.
5. 9 Cost Model
5.9.1 Costs
The total production cost can be broken down into two categories: fixed cost elements
and variable cost elements. Fixed cost elements are those that do not change depending on the
number of batches made, and for this cost model include the machinery cost and the overhead
cost. Variable cost elements are those that do change depending on the number of batches made
and include the material, energy, and labor cost. There are a number of other cost categories that
should be considered in a thorough cost model but the following estimation is only meant to give
to give a general idea of production costs. Further, the cost model is meant to represent a pilot
production facility, such as in a university lab or something slight bigger; it is not meant to
represent full-scale production. A cost model considering full-scale production would differ in
that higher-capacity and more equipment would be needed but the cost of things would decrease
because things are usually cheaper when bought in bulk. A description of how the estimates for
each of the five cost categories (materials, energy, labor, machinery, and overhead) were made is
given below.
The costs of the raw materials required to produce the bone-ligament scaffold are
minimal. Table 14 lists the potential suppliers for these materials and their prices.
'Man.x ½usicr Seccdrv Sourý,e
______ _ COaMp i · Cost C'cuaM  1 Onnp! C pn
vlIz·en De'z~o c ai..-Affs Amtl: al 7 P.ý .S DZ z
phos'hzm1 adýS,!Irna A:.drizb U K, US 2 EmL BDr LTK U S5
cubadjodmtde cm-linken Sir, _=M2 S\; I BBDH U ID~ U
Table 14. Raw Materials Sources and Prices. (Taken From OrthoMimetics, 2006)
Using these prices, a calculation for the cost of a single bone-ligament scaffold for a
replacement patellar tendon and a replacement ACL can be made. The first step in making these
calculations was approximating the size of these scaffolds. A schematic of a patellar tendon
graft is shown in Figure 30.
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Figure 30. Schematic of Patellar Tendon Graft Used in ACL Replacement. (Taken From Staehelin, 1996)
The patellar tendon graft is usually about 10 mm wide, as viewed anteriorly, and 90 mm
long. The two bone segments are each about 25 mm long, for a combined length of 50 mm of
bone and 40 mm of tendon. Although the diameter of the graft changes, for the purposes of the
calculation, it was taken to be constant at 10 mm. It was assumed that an ACL scaffold would be
a similar size as the patellar tendon graft. The ACL graft was estimated to be 90 mm long, but
with bone segments of 40 mm and 25 mm, as indicated in Figure 30. Essentially, the graft's
shapes were estimated to be a cylinder with a ligament section in between two bone sections.
Using these volumes and assuming the bone scaffold would be 90% CaP by weight, the costs of
the patellar tendon scaffold and ACL scaffold, based on raw material cost alone, were calculated
as $33.22 and $33.34, respectively.
In order to determine the energy costs, the processing was broken down into three main
steps: (1) blending with a refrigerant system, (2) blending without a refrigerant system, and (3)
freeze-drying. These steps were chosen because they were the ones that would require the use of
specialized equipment which would be expensive and would use a significant amount of energy.
The equipment needed for these three steps are a motor-stator homogenizer, a refrigerant system,
and a freeze-dryer. Data for the average prices and average energy usage for the equipment was
found and is shown in Table 15. Data for the homogenizer was based off the price and energy
usage of the Pro250 Homogenizer from PRO Scientific (PRO Scientific). Data for the freeze-
dryer was based off price and energy usage of the Genesis from VirTis and the Dura-Dry II from
FTS Systems (VirTis; FTS Systems). Information on a refrigerant system for use during
blending could not be found. The cost was estimated to be around $10,000, and the energy usage
was estimated to be the same as a refrigerator, 300W. The cost of energy used in this calculation
was $0.085/kW-hr, which was the US national average cost in April 2006 (EIA, 2006). Using
this information and the times to complete each processing step (see Table 16), a rough estimate
of the energy cost per year was made. Using the times from Table 16, it was approximated that
the entire production time for one batch would be 2.5 days if in operation 24 hours per day. This
means that in one week, two batches could be produced, and in one year, 100 batches could be
produced, assuming 50 work weeks. In order to determine costs per unit, the number of
scaffolds per batch was determined. The typical freeze-dryer for laboratory or pilot production
use has three shelves, each with the dimensions of 28 cm by 50 cm. Assuming the size of each
scaffold to be 1 cm by 9 cm and that the scaffolds would not be made directly next to each other,
it was calculated that in a freeze-dryer with three shelves of this size approximately 200 scaffolds
could be made in one batch. This means in one week, 400 scaffolds could be produced and in
one year, 20,000 scaffolds could be produced.
Cost Energy Usage
Blender/Homogenizer $2,000 576 W
Freeze-Dryer $35,000 372.85 W
Refrigerant System 300W
Table 15. Average Price and Energy Usage for Machinery.
Processing Step Time (hr
Blending With Refrigerant System 3.25
Blending Without Refrigerant System 24
Freeze-Drying 23.58
Total 50.83
Table 16. Processing Step Times To Produce One Batch.
In terms of labor, it was assumed that two skilled technicians would be needed at all
times, and it was estimated that such a person would have a salary of $30/hour. This allows for a
calculation of labor cost per year. The machinery costs would be an initial investment but it its
cost per year would actually depend on how long the machinery lasted. For the sake of this cost
model, it was assumed the machinery would be used for one year and the cost of each piece of
machinery would be spread out over that one year. This means the machinery cost was just the
cost to buy all the machinery. The overhead cost includes the cost of rent for the building and
the basic utility costs. It was assumed that this cost would be about 15% of the total cost. The
production cost per year and per unit is shown in Table 17. It was assumed that the material cost
for both the ACL and patellar
products.
tendon scaffold would be $34, so Table 17 applies to both
Cost Per Year Cost Per Unit Percent of Total Cost
Variable Cost Elements
Material Cost $680,000 $34 63.88%
Energy Cost $216.44 $0.01 0.02%
Labor Cost $187,200 $9.36 17.59%
Total Variable Cost $1,054,616.44 $43.37 81.49%
Fixed Cost Elements
Machinery Cost $47,000 $2.35 4.42%
Overhead Cost $150,000 $7.50 14.09%
Total Fixed Cost $59,000 $9.85 18.51%
Total Cost $1064416.44 $53.22 100%
Table 17. Breakdown of Cost Per Year of Production and Per Unit of Production.
5.9.2 Profits
Using the estimates of scaffold production cost and the proposed prices from Section 5.8,
a profit per unit can be calculated, see Table 18. For the case of the patellar tendon scaffold, the
lower price was used for a more conservative approach.
Price - Cost = Profit
Patellar Tendon $600 - $53 = $547
ACL $900 - $53 = $847
Table 18. Profit per Unit.
How these profits per part translate into total profits depends on how much of the market
share the products obtain. Due to the low risk of device failure or complication, potential
benefits, and the absence of competitors, the patellar tendon graft site scaffold could potentially
obtain 100% of the market. Of course, the likelihood off this happening is practically zero
because there will always be reasons certain portions of the market won't use or accept a product.
For example, in the US, Apple Computer Inc's portable mp3 music player, the iPod, has almost
70% of the digital music player market, but worldwide it only has about 25% of the market
(Marsal, 2006). These market shares provide a good way to estimate the market share the
patellar tendon graft site scaffold may attain even though the digital music player market, both in
the US and the world, is very different from the market for the patellar tendon graft site scaffold.
If we assume the scaffold becomes as ubiquitous in the world of ACL surgery as the iPod is in
the US, a market share of 70% is predicted. A medium market share is estimated to be 55% and
a low market share to be 30%. Using the market size value from Section 5.1, these market
shares lead to yearly sales of 394,600, 310,000, and 169,100 and profits of $216 million, $170
million, and $92 million, respectively. For the ACL scaffold, a much lower market share is
likely to be obtained due to the presence of competitive treatments, both current and new ones,
the increased risk of failure, and surgeons' hesitance to use something new and unproven. When
trying to determine a price for the ACL scaffold, it was compared to an allograft. If this
comparison is used again, then one can assume somewhere between five to twenty-five percent
of the market will be obtained, just like the allograft (See Section 5.1). The high, medium, and
low market share is estimated to be 25%, 15%, and 5%, respectively. Using the market size
value from Section 5.1, these market shares lead to yearly sales of 229,500, 137,700, and 45,900
with profits of $194 million, $116 million, and $39 million, respectively.
The results of this cost model should be considered carefully. These simple calculations
only take into account some of the total costs that would be incurred and the cost model was
meant to represent a small-scale pilot production facility, not a large-scale production facility.
Further, the actual business plan is to out-source the manufacturing, which means the actual cost
to manufacture could be significantly different depending on how much the manufacturer
charges. These calculations also do not take into account the terms of the license from CMI,
which specifies royalties on sales. On the other hand, in addition to money made from sales of
the scaffolds, money could also be made via sub-licensing of the technology. As mentioned
earlier, the use of including cells with implants to improve healing is being extensively
researched. Our scaffold could prove to be the perfect delivery device for these cells, in which
case, we could license our technology in return for a share of the profits. Despite this
calculation's simplicity, it does provide an illustration of the potential profits of the two products.
Chapter 6. Conclusion
Within this thesis, the possibility of the commercial application of a bi-layer bone-
ligament scaffold to ACL replacement was explored. A review of the technology itself led to the
conclusion that while the scaffold effectively mimics the basic structure of natural bone and
ligament, it does not yet have the mechanical properties needed for an implant. During the
process of creating a business plan for this technology, it became clear that the probability of
commercial success for an ACL scaffold would be small due to the increased mechanical
property requirements and the difficulty in convincing surgeons to try this new solution. On the
other hand, the commercial success of a patellar tendon graft site scaffold looks feasible given
the potential benefit of avoiding donor site morbidity and its symptoms and the ease of device
implantation. A very basic cost model showed that the possible profits of either of these
products could be substantial due to the low costs of the raw materials.
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Appendix A. All Collected Compact Bone Mechanical Property Data.
The following four data tables show all the collected compact bone mechanical property
data. The four tables represent the data found for specimens tested longitudinally and wet,
longitudinally and dry, transversely and wet, and transversely and dry. The mechanical
properties for which data was collected were the tensile and compressive elastic modulus,
ultimate stress, and ultimate strain. The source, given as the book's author and the page number,
is shown for all data points. At the end of the table, the average values and the number of data
points for all the properties are given (See Table 4).
The data from Evans was originally given in units of lbf/in 2 and kgf/mm2. It was
converted into Pascals (Pa) using
kgf/mm2 = 9,806,650 Pa.
the following conversions: (1) 1 lbf/in2 = 6.895 Pa and (2) 1
Tensile CompressiveSource(Author, Elastic Ultimate Ultimate Elastic Ultimate Ultimate
Pg. No.) Modulus Stress Strain Modulus Stress Strain
(GPa) (MPa) (%) (GPa) (MPa) (
Evans, 51 15.65 81.64 1.2
Evans, 52 12 65.04 1.4895
Evans, 53 11.93 78.8 14.2 108.77
12.2 14.07
Evans, 59 17.17 93.18 1.55439
14.76 84.74 1.95872
Evans, 84 95.28
90.1
83.36
87.48
128.66
Evans, 90 131.05
199.96
Evans, 108 8.7
Evans, 162 76.18 136.58
80.69 140.8
100.42 164.62
95.5 200.21
121.58 205.11
103.44 207.86
103.74 152.37
122.56 132.36
149.03 114.71
148.05 117.66
121.58 166.68
140.21 158.83
146.09 122.56
95.24 84.59
63.86 110.02
88.42 127.56
100.13
Evans, 163 1.45 1.9
1.5 2
1.49 2
1.41 1.8
1.5 1.9
1.59 2.1
1.47 0.61
1.7 1.53
1.79 1.25
Evans, 164 22.06
23.44
17.03
17.31
17.17
18.55
18.41
17.24
18.06
18.55
11.72
16.69
15.1
Evans, 164 14.48 78.31 1.46
15.88 92.66 1.77
17.44 92.57 1.71
Evans, 172 17.58 174.79
19.44 181.34
12.69 179.27
15.44 117.39
15.79 101.74
14.45 88.08
Evans, 184 14.41 78.14 1.46
Evans, 185 15.86 92.71 1.76
Evans, 186 17.38 92.19 1.67
Evans, 186 16.82 88.92 0.6
Evans, 187 16.75 88.37 1.67
Evans, 188 19.1 108.23 0.89
Currey, 56 17.7 18.2
Currey, 59 133 3.1 205 1.9
Currey, 60 158 4.2 213 2.6
Currey, 130 16.7 166 2.9
Average 16.50 102.79 1.77 15.42 148.26 1.71
Number of
o 29 38 24 12 29 13Data Points
Table 19. All Collected Mechanical Property Data for Compact Bone Tested Longitudinally and Wet.
Tensile CompressiveSource(Author, Pg. Elastic Ultimate Ultimate Elastic Ultimate Ultimate
No.) Modulus Stress Strain Modulus Stress Strain
(GPa) (Mpa) (%) (GPa) (Mpa) (%)
Evans, 51 18.41 107.08 0.66
Evans, 52 19.76 102.05 0.455
Evans, 53 18.55 117.84 17.93 177.06
19.72 17.44
Evans, 84 137.48
131.96
Evans, 90 190.99
169.03
133.83
174.79
140.66
191.51
203.92
Evans, 108 12.11
Average 19.11 119.28 0.56 15.83 172.72
Number of 4 5 2 3 8Data Points
Table 20. All Collected Mechanical Property Data for Compact Bone Tested Longitudinally and Dry.
Tensile CompressiveSource(Author, Pg. Elastic Ultimate Ultimate Elastic Ultimate Ultimate
No.) Modulus Stress Strain Modulus Stress Strain
(GPa) (MPa) (%) (GPa) (MPa) (%)
Evans, 84 9.87
15.84
15.12
56.09
Evans, 90 117.13
150.31
Evans, 108 3.76
Currey, 56 12.8 11.7
Currey, 59 53 0.7 131 5
Average 12.8 29.984 0.7 7.73 132.813 5
Number of
1 5 1 2 3 1Data Points
Table 21. All Collected Mechanical Property Data for Compact Bone Tested Transversely and Wet.
Tensile CompressiveSource
Elastic Ultimate Ultimate Elastic Ultimate Ultimate(Author, Pg.
No.) Modulus Stress Strain Modulus Stress Strain (%)
(GPa) (MPa) (%) (GPa) (MPa)
Evans, 84 11.36
Evans, 90 174.51
123.56
110.8
193.75
166.86
132.4
Evans, 108 6.32
Average - 11.36 - 6.32 150.31
Number of
-1 - 1 6Data Points
Table 22. All Collected Mechanical Property Data for Compact Bone Tested Transversely and Dry.
Appendix B. All Collected Cancellous Bone Mechanical Property Data.
The following table shows all the cancellous bone mechanical property data found during
an extensive literature review. The source of all data is given. The minimum and maximum
values are shaded and are the values used in Table 5 in Section 3.2.5. All of the mechanical
property data is for wet bone tested in compression because no data could be found for dry bone
or tensile properties. However, for all the data the density was determined using the specimen
when dry.
The elastic modulus and ultimate strength data from Evans was originally given in units
of lbf/in2 and kgf/mm2 . It was converted into Pascals (Pa) using the following conversions: (1)
1 lbf/in2 = 6.895 Pa and (2) 1 kgf/mm2 = 9,806,650 Pa. That data was taken from human femoral
bone and the direction refers to the axis along which the bone was loaded: sup-inf is superior-
inferior, ant-post is anterior-posterior, and lat-med is lateral-medial.
The data from Mow, pg. 87 and Currey, pg. 152 were read from graphs (See Figure 18
and Figure 19, respectively), which adds a degree of uncertainty to these values.
Source
Pg. No.
Direction
Min
Max
Avg
Min
Max
Avg
Min
Max
Avg
Min
Max
Avg
Evans,
1973
114
Sup- Ant- Along Lat-
Inf Post neck Med
0.293 0.273 0.575 0.217
1.020 1.17 0.98 1.083
0.682 0.672 0.822 1
0.0429 0.0358 0.0862 0.0401
0.8274 0.6916 0.5747 0.9748
0.245 0.21 0.3858 0.6141
0.393 0.3034 1.14 0.1103
9.52 5.5 6.82 14.82
2.77 2.25 4.32 4.13
1.1 1.5 1.7 2
7.8 3.9 2.5 28.9
3.02 2.24 2.02 3.2
Mow,
1997
86
N/A
0.1
1
Mow,
1997
87
N/A
1
0.01
2
Currey,
2002
152
N/A
0.18
0.6
0.03
0.3
0.6
18
Currey,
2002
156
N/A
0.00350.35
Table 23. All Collected Cancellous Bone Material Property Data. The Shaded Boxes Represent the Absolute
Minimum or Maximum Value for that Property and are the Values Used in Table 5.
Density
(g/cm3)
Elastic
Modulus
(GPa)
Ultimate
Strength
(MPa)
Ultimate
Strain
(%)
~i-
Density (g/cm 3)
Elastic Modulus (GPa)
Ultimate Strength (MPa)
Ultimate Strain (%)
Min
Max
Avg
Min
Max
Avg
Min
Max
Avg
Min
Max
Avg
Average Value
0.245
0.979
0.794
0.0356
0.8169
0.364
0.4411
24.11
3.3675
1.575
10.775
2.62
Table 24. Average Values For the Data in Table 23.
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Appendix C. All Referenced Patents and Other Relevant Patents.
(Listed by US Patent Number.)
US Patent Number
Date Patent Issued
First Listed Inventor
Assignee(s)
4060081
November 29, 1977
Yannas, loannis V.
Massachusetts Institute of Technology
(Cambridge, MA)
4280954
July 28, 1981
Yannas, Ioannis V.
Massachusetts Institute of Technology
(Cambridge, MA)
4522753
June 11, 1985
Yannas, loannis V.
Massachusetts Institute of Technology
(Cambridge, MA)
5131850
July 21, 1992
Brockbank, Kelvin G. M.
Cryolife, Inc. (Marietta, GA)
5522895
June 4, 1996
Mikos, Antonios G.
Rice University (Houston, TX)
Patent Title:
Patent Abstract (taken directly from patent)
Multilayer Membrane Useful as Synthetic Skin: A multilayer
membrane, which is useful as synthetic skin, is disclosed herein.
A first layer is formed from a material which does not provoke an
immune response and which is also insoluble and nondegradable
in the presence of body fluids and/or body enzymes. Preferred
materials for the first layer are crosslinked composites of
collagen and a mucopolysaccharide. A second layer is formed
from a nontoxic material which controls the moisture flux of the
overall membrane to about 0.1 to 1 mg./cm.sup.2 /hr. Suitable
materials for the second layer include synthetic polymers such as
silicone resins, polyacrylate or polymethacrylate esters or their
copolymers, and polyurethanes.
Crosslinked Collagen-Mucopolysaccharide Composite Materials:
Composite materials are disclosed which are formed by
contacting collagen with a mucopolysaccharide and subsequently
covalently crosslinking the resultant polymer. These composite
materials have a balance of mechanical, chemical and
physiological properties which make them useful in surgical
sutures and prostheses of controlled biodegradability (resorption)
and controlled ability to prevent development of a foreign body
reaction, and many are also useful in applications in which blood
compatibility is required.
Method of Preserving Porosity In Porous Materials: A method
for preserving the porosity of porous materials is disclosed. In
this method, the porous material is subjected to elevated
temperature and vacuum conditions to thereby produce a
dimensionally-stable, non-collapsible porous material.
Method for Cryopreserving Muskoskeletal Tissues: Disclosed
herein is a method for cryopreserving musculoskeletal tissues,
such as ligaments, tendons and cartilage, by placing such tissue
in contact with a composition containing a cryopreserving agent
comprising a cell-penetrating organic solute, which is preferably
dimethylsulfoxide, and a glycosaminoglycan, which is preferably
chondroitin sulphate, in an amount sufficient to cryopreserve the
musculoskeletal tissue. Also disclosed are a freezing schedule
designed to maximize retention of tissue cell viability and
biomechanical properties during and after the freezing process,
and a thawing schedule which maximizes cell viability.
Biodegradable Bone Templates: A biodegradable, bioresorbable,
three-dimensional template for repair and replacement of
diseased or injured bone which provides mechanical strength to
bone while also providing a guide for growth of bone tissue.
Preferably, the template is formed of biodegradable materials, for
example, poly(L-lactic acid), poly(D, L-lactic acid), poly (D, L-
lactic-co-glycolic acid), poly (glycolic acid), poly (.epsilon.-
6077989
June 20, 2000
Kandel, Rita
N/A
6287340
September 11, 2001
Altman, Gregory
Trustees of Tufts College
(Boston, MA)
Massachusetts Institute of Technology
(Cambridge, MA)
6332779
December 25, 2001
Boyce, Todd M.
Osteotech, Inc. (Eatontown, NJ)
6402783
June 11, 2002
Stone, Kevin R.
CrossCart, Inc. (San Francisco, CA)
caprolactone), polyortho esters, and polyanhydrides. A pore-
forming component, which may or may not be a polymeric
material, is mixed within a continuous matrix formed of a
biodegradable material, the pore-forming component having a
rate of degradation which exceeds that of the matrix.
Resorbable Implant Biomaterial Made of Condensed Calcium
Phosphate Particles: A resorbable biomaterial for implantation in
humans and other animals comprises amorphous or crystalline
condensed calcium phosphate. The condensed calcium phosphate
powder can be formed as a sintered powder which is bound or
consolidated to form at least part of an implantable anchor, with
controlled size and amount of porosity. The condensed calcium
phosphate may be used to replace hard connective tissues, or to
regenerate soft connective tissues by providing a support on
which soft tissue may be grown in vitro or in vivo, or to anchor
soft connective tissue to bone.
Bioengineered Anterior Cruciate Ligament: The present
invention provides a method for producing an anterior cruciate
ligament ex vivo. The method comprises seeding pluripotent
stem cells in a three dimensional matrix, anchoring the seeded
matrix by attachment to two anchors, and culturing the cells
within the matrix under conditions appropriate for cell growth
and regeneration, while subjecting the matrix to one or more
mechanical forces via movement of one or both of the attached
anchors. The method for producing an anterior cruciate ligament
can be adapted to produce a wide range of tissue types ex vivo by
adapting the anchor size and attachment sites to reflect the size of
the specific type of tissue to be produced, and also adapting the
specific combination of forces applied, to mimic the mechanical
stimuli experienced in vivo by the specific type of tissue to be
produced. Some examples of tissue which can be produced
include other ligaments in the body (hand, wrist, elbow, knee),
tendon, cartilage, bone, muscle, and blood vessels.
Method of Hard Tissue Repair: A method for promoting the
growth of bone, periodontium, or ligament in a warm-blooded
vertebrate, the method comprising: producing a surgical flap to
expose the bone, periodontium or ligament; debriding the bone,
periodontium or ligament to remove organic matter from the
bone, periodontium or ligament; implanting an effective amount
of an osteogenic bone graft material, the bone graft material
consisting of an osteoimplant having not greater than about 32%
void volume formed at least in part from elongate bone-derived
elements optionally in combination with bone powder; replacing
the flap; and, allowing the bone, periodontium or ligament to
regrow.
Anterior Cruciate Ligament Xenografts: The invention provides
an article of manufacture comprising a substantially non-
immunogenic ligament or tendon xenograft for implantation into
humans. The invention further provides a ligament xenograft for
implantation into a human including a portion of a ligament from
a non-human animal, wherein the portion includes extracellular
components and substantially only dead cells. Each of the
xenografts of the invention is substantially non-immunogenic and
has substantially the same mechanical properties as the respective
native ligament.
Resorbable Scaffolds to Promote Cartilage Regeneration: A
load-sharing resorbable scaffold is used to help transplanted
chondrocytes or other cells generate new cartilage in a damaged6530956 joint such as a knee, hip, or shoulder. These scaffolds use two
March 11, 2003 distinct matrix materials. One is a relatively stiff matrix material,
Mansmann, Kevin A. designed to withstand and resist a compressive articulating load
N/A placed on the joint during the convalescent period, shortly after
surgery. The second material comprises a more open and porous
matrix, designed to promote maximal rapid generation of new
cartilage.
Resorbable, Macro-Porous Non-Collapsing and Flexible
Membrane Barrier for Skeletal Repair and Regeneration: A
6712851 resorbable, flexible implant in the form of a continuous macro-
March 30, 2004 porous sheet is disclosed. The implant is adapted to protect
biological tissue defects, especially bone defects in the
Lemperle, Stefan M. mammalian skeletal system, from the interposition of adjacent
MacroPore Biosurgery, Inc. soft tissues during in vivo repair. The membrane has pores with
(LaJolla, CA) diameters from 20 microns to 3000 microns. The sheet provides
enough inherent mechanical strength to withstand pressure from
adjacent musculature and does not collapse.
Tissue Regeneration Matrices by solid Free-Form Fabrication
Techniques: Solid free-form (SSF) techniques for making
medical devices for implantation and growth of cells from
polymers or polymer/inorganic composites using computer aided
design are described. Examples of SFF methods include stereo-
lithography (SLA), selective laser sintering (SLS), ballistic
particle manufacturing (BPM), fusion deposition modeling
March 11, 2003 (FDM), and three dimensional printing (3DP). The devices can
Cima, Linda G. incorporate inorganic particles to improve the strength of the
Massachusetts Institute of Technology walls forming the pores within the matrix and to provide a source
(Cambridge, MA) of mineral for the regenerating tissue. The devices can contain
tissue adhesion peptides, or can be coated with materials which
reduce tissue adhesion. The macrostructure and porosity of the
device can be manipulated by controlling printing parameters.
Most importantly, these features can be designed and tailored
using computer assisted design (CAD) for individual patients to
optimize therapy.
Tissue-Engineered Ligament: An apparatus and method for the
reconstruction of a previously torn ligament using a tissue-
6737053 engineered ligament. The tissue-engineered ligament includes a
May 18, 2004 scaffold of biocompatible material having at least one layer andforming a sheet. The scaffold is placed in a cultured medium for
Goh, James Cho Hong seeding with fibrocyte forming cells. The seeded scaffold is then
National University of Singapore (SG) placed in an incubator to increase the number of cells. The
seeded scaffold is then formed into a slender structure suitable
for implantation.
Membrane for In Guided Tissue Regeneration: The invention
provides a multi-layer membrane comprising a matrix layer
June 22, 2004 predominantly of collagen II and having an open sponge-like
Geistlich, Peter texture, and at least one barrier layer having a close, relatively
Ed Geistlich Soehne AG Fuer impermeable texture. Such a membrane is particularly suitable
Chemische Industrie for use in guided tissue regeneration, in particular for use in vivo
in the reconstruction of bone or cartilage tissue.
6866991 Methods for Promoting Bone, Ligament, and Cartilage using
zvegf4: Methods for promoting growth of bone, ligament, or
March 15, 2005 cartilage in a mammal are disclosed. The methods comprise
Gilberston, Debra G.
ZymoGenetics, Inc. (Seattle, WA)
6867247
March 15, 2005
Williams, Simon F.
Metabolix, Inc. (Cambridge, MA)
6887488
May 3, 2005
Cui, Fuzhai
Tsinghua University (Beijing, China)
6893462
May 17, 2005
Buskirk, Dayna
Regeneration Technologies, Inc.
(Alachua, FL)
6902932
June 7, 2005
Altman, Gregory H.
Tissue Regeneration, Inc.
(Medford, MA)
6919308
July 19, 2005
Oppermann, Hermann
Stryker Corporation (Kalamazoo, MI)
administering to said mammal a composition comprising a
pharmacologically effective amount of zvegf4 in combination
with a pharmaceutically acceptable delivery vehicle.
Medical Devices and Applications of Polyhydroxyalkanoate
Polymers: Devices formed of or including biocompatible
polyhydroxyalkanoates are provided with controlled degradation
rates, preferably less than one year under physiological
conditions. Preferred devices include...bone plates and bone
plating systems.. orthopedic pins (including bone filling
augmentation material)...guided tissue repair/regeneration
devices, articular cartilage repair devices, nerve guides, tendon
repair devices...bone marrow scaffolds, meniscus regeneration
devices, ligament and tendon grafts...bone graft substitutes, bone
dowels, wound dressings, and hemostats. The
polyhydroxyalkanoate compositions also provide favorable
mechanical properties, biocompatibility, and degradation times
within desirable time frames under physiological conditions.
Nano-calcium phosphates/collagen based bone substitute
materials: The present invention relates to a nano-calcium
phosphates/collagen composite that mimics the natural bone,
both in composition and microstructure, as well as porous bone
substitute and tissue engineering scaffolds made by a complex of
said composite and poly(lactic acid)(PLA) or poly(lactic acid-co-
glycolic acid)(PLGA). The invention also relates to the use of
said scaffold in treating bone defect and bone fracture.
Soft and Calcified Tissue Implants: Disclosed herein is
processed dermis graft for use in orthopedic surgical procedures.
Specifically exemplified herein is a processed dermis graft
comprising one or more bone blocks having a groove cut into the
surface thereof, wherein said groove is sufficient to accommodate
a fixation screw. Also disclosed is a method of processing dermis
that results in a dermis derived implant suitable to replace a
tendon or ligament in a recipient in need thereof. Other
compositions and applications of a dermis derived implant, and
methods of manufacture and use, are disclosed.
Helically Organized Silk Fibroin Fiber Bundles for Matrices in
Tissue Engineering: The present invention provides a novel silk-
fiber-based matrix having a wire-rope geometry for use in
producing a ligament or tendon, particularly an anterior cruciate
ligament, ex vivo for implantation into a recipient in need
thereof. The invention further provides the novel silk-fiber-based
matrix which is seeded with pluripotent cells that proliferate and
differentiate on the matrix to form a ligament or tendon ex vivo.
Osteogenic Devices: Disclosed are (1) osteogenic devices
comprising a matrix containing substantially pure natural-sourced
mammalian osteogenic protein; (2) DNA and amino acid
sequences for novel polypeptide chains useful as subunits of
dimeric osteogenic proteins; (3) vectors carrying sequences
encoding these novel polypeptide chains and host cells
transfected with these vectors; (4) methods of producing these
polypeptide chains using recombinant DNA technology; (5)
antibodies specific for these novel polypeptide chains; (6)
osteogenic devices comprising these recombinantly produced
proteins in association with an appropriate carrier matrix; and (7)
methods of using the osteogenic devices to mimic the natural
course of endochondral bone formation in mammals.
6946003
September 20, 2005
Wolowacz, Sorrel
Smith & Nephew plc (London, GB)
6972130
December 6, 2005
Lee, Dosuk D.
Etex Corporation (Cambridge, MA)
Implants for Connective Tissue Regeneration: Biocompatible,
implantable material comprising flexible, elongate tape and a
plurality of elongate elements, each elongate element being
aligned along and independently translatable in the longitudinal
direction of the tape; implants manufactured from this material,
for the partial or total replacement or reinforcement of connective
tissue such as ligament, cartilage, bone, meniscus tendon, skin.
Bioceramic Compositions: The present invention provides a
synthetic, poorly crystalline apatite (PCA) calcium phosphate
containing a biologically active agent and/or cells (preferably
tissue-forming or tissue-degrading cells). The compositions
provided by the present invention are useful for a variety of in
vivo and in vitro applications, including drug delivery (for
example, to bony sites, the central nervous system, intramuscular
sites, subcutaneous sites, interperitoneal sites, and occular sites)
tissue growth (preferably bone or cartilage) osseous
augmentation, and methods of diagnosing disease states by
assaying tissue forming potential of cells isolated from a host.
Appendix D. Terms of the Licensing Agreement Between
OrthoMimetics Limited and the Cambridge-MIT Institute (CMI).
The following outlines the terms of the licensing agreement between OrthoMimetics
Limited and CMI. It comes directly from the business plan for OrthoMimetics (OrthoMimetics,
2006).
* Minimum Annual Royalty: £5,000 from 2007 to 2010; £10,000 from 2010 to 2014;
£30,000 from 2015 until patent expiration
* Royalties on Net Sales Value: 1.0% on net sales of less than £25M; 1.5% on net sales of
£25M to £75M; 2.0% on net sales above £75M
* Equity: 12% in ordinary shares, pre-money, fully diluted
* Sublicensing Revenue: 10% of all income derived from sublicensing
* Reimbursement of Patent Costs Incurred to Date: - £15,000 for three patent applications
* Equity-Convertible Milestone Payments: £25,000 upon commencement of first clinical
trial; £100,000 upon receipt of first regulatory approval from a major regulatory body
(milestone payments payable in cash-value equivalent in ordinary shares at the time of
realization; payments revert to cash in the even that a change of company control occurs)
Appendix E. Population Data for the United States, the European
Union, and Japan from 1991 - 2010.
The US and Japanese population data was taken from the International Data Base, which
is a computerized source of demographic and socioeconomic statistics for 227 countries and
areas. It was created by the US Census Bureau's International Programs Center. While it could
also have been used to obtain population data for the EU, it was decided to use the data from
Eurostat, the Statistical Office of the European Commission. First, they could provide data for
the group of countries comprising the 25 members of the European Union. Also, as this data was
from the Statistical Office of the European Commission, it was thought that it would be more
accurate, even though it didn't provide values for all the years in between 1991 and 2010. The
following table gives the number of inhabitants within the specified region as calculated and
projected from censuses. The data was used to determine the market sizes for the ACL graft and
the patellar tendon donor site graft.
Year US EU Japan
1991 253,492,503 - 123,946,268
1992 256,894,189 124,329,269
1993 260,255,352 - 124,668,019
1994 263,435,673 444,860,000 125,014,050
1995 266,557,091 445,871,200 125,341,354
1996 269,667,391 446,816,600 125,645,311
1997 272,911,760 447,710,300 125,956,499
1998 276,115,288 448,478,900 126,246,096
1999 279,294,713 449,241,600 126,494,403
2000 282,338,631 450,378,800 126,699,784
2001 285,023,886 451,388,100 126,891,645
2002 287,675,526 452,990,300 127,065,841
2003 290,342,554 455,022,900 127,214,499
2004 293,027,571 457,189,000 127,333,002
2005 295,734,134 459,488,400 127,417,244
2006 298,444,215 - 127,463,611
2007 301,139,947 - 127,467,972
2008 303,824,646 - 127,425,722
2009 306,499,395 - 127,334,743
2010 309,162,581 464,100,000 127,194,656
Table 25. Population Data for the US, the EU, and Japan from 1991 - 2010.
Appendix F. Rates of Inpatient Surgical Procedures Within the United
States and the European Union.
Inpatient surgical procedures rates for the EU were taken from Eurostat, the Statistical
Office of the European Commission. The data provided by Eurostat was given as an incidence
rate for each reporting country, which differed from year to year and depending on the surgical
procedure. This data was then averaged over all the countries and assumed to be the average for
the entire EU. Eurostat only had incidence rates (per 100,000 people) for operations on the
musco-skeletal system, knee arthroscopy, and total hip replacement, represented by the codes 76
to 84, 80.26 to 80.6, and 81.51, respectively, in the International Classification of Diseases, 9t"
Revision, Clinical Modification (ICD-9-CM). Eurostat did not provide information on ACL
surgeries alone, represented by ICD-9-CM code 81.45. Inpatient surgical procedure rates for the
US were taken from the Healthcare Cost and Utilization Project (HCUPnet). The incidence rates
between the EU and the US were compared and it was found that the EU incidence rate was, on
average, 1.3974 times higher.
Table 26. Rate of Inpatient Musco-skeletal Systems Operations in EU Countries.
Belgium
Denmark
Germany
Estonia
Greece
Spain
Italy
Cyprus
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Poland
Portugal
Slovenia
Slovakia
Finland
Sweden
United
Kingdom
2000
1676.4
1063.3
902.9
1437.4
325.1
972.5
935.8
868.6
611.2
802.2
2146.5
1541.1
1248.7
1997
2330.3
1595.9
796.4
176.9
827.4
1134.5
292.4
723.9
699.3
956.4
714.4
2045.3
1168.3
1998
2361.8
1596.6
999
228.3
915.1
1337
288.2
894.2
816.3
911.5
736.9
2059.9
1594.4
1245.6
2003
1626.6
957.4
294.8
1132.4
1162.8
763.3
716.7
911.4
2178.4
1549.7
1370.3
2001
1617.9
1068.5
950.1
1491.2
296.5
1002.4
995.5
878.4
626.3
1214.7
794.8
2052
1512
1252.8
1999
1614
1018.2
212.9
856.4
1405.1
289.3
972.3
907
897
754.4
2090.8
1620.7
1253.8
2002
1130.3
948.3
1567.7
313.1
1101.9
1103.3
912.3
674.7
1272.5
866.5
2179.1
1542.7
1313.2
Belgium
Denmark
Germany
Estonia
Greece
Spain
Italy
Cyprus
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Poland
Portugal
Slovenia
Slovakia
Finland
Sweden
United
Kingdom
Table 27. Rate of Inpatient Knee Arthroscopy Operations in EU Countries.
1997
413
69.2
71.8
60.3
92.3
157
141.6
45.6
1998
372
60.2
137.8
74.9
110.2
265.6
134.8
15.9
47.6
1999
63.9
149.4
71.9
129.8
276
120.3
13.7
43.6
2000
56.2
120.2
99.3
279.7
39.1
112.9
10.9
40.2
2001
44.5
139.3
99.3
309.7
41
103.7
89.4
10.2
37.3
2002
149.6
91
320.2
52.4
99.5
89.7
9.9
40.9
2003
84.7
88.2
79.3
56.9
84.4
9.8
40.5
Table 28. Rate of Inpatient Total Hip Replacement Operation in EU Countries.
Musco-skeletal systems operations 1.4173
Knee Arthroscopy 1.3707
Total Hip Replacement 1.4042
Average 1.3974
Table 29. Comparison of Ratios between EU and US Operation Incidence Rates.
1997 1998 1999 2000 2001 2002 2003
Belgium 179.7 183.9
Denmark 89.7 90.2 92.4 101 98.3
Germany
Estonia 62 84.3 99.5 104.5 126.6 161.2 86.9
Greece 45 61.3 63.3
Spain 40.2 41.9 40.8 42.1 47.6 48.5 48.7
Italy 102.9 69.7 72.6 75.6 78 83.3
Cyprus 33.3 16.8 9.3 19.5 17.9 16.3 14.7
Latvia 64.7 65.9 63.6 68 68.7 71.2
Lithuania
Luxembourg 192.1 186.8 193.8 213.3 211.7
Malta 9.7 12.2
Netherlands
Poland 27.5
Portugal 43.1 47.1 48.3 48.3
Slovenia 97.7 99.8
Slovakia
Finland 86.1 86.5 88.5 94.5 97.9 107.5 111.8
Sweden 128.8 119.2 125 130.4 137 137.8
United 85.7 93.5 93 95.8 98.4 106 115.6Kingdom
Appendix G. Boston Medical Center Anterior Cruciate Ligament
Surgery Data From Dr. William Creevy.
Surgery Time Operating Room Charges Total Charges
(hours) (US $) (US $)
3 6744 13,767
2.5 6180 13,260
2.25 5562 11,883
3.25 7306 14,721
3 6744 14,030
2.25 5562 12,601
3.25 7306 14,597
3 7416 13,335
2.5 5620 13,603
3 6744 13,559
2.75 6182 13,372
2.25 5058 11,715
2.25 5058 11,643
2.75 6182 11,479
2.5 5620 10,657
2 4496 10,512
1.75 3934 9,471
2.25 5058 8,282
4.5 10116 19,769
3 6744 13,565
2.75 6182 14,202
2.75 6182 13,155
2.5 5620 12,722
2.5 5620 12,064
3.75 9270 20,523
3.25 7306 15,170
3 6744 14,433
3.25 7306 14,145
3.25 7306 13,747
2.5 5620 12,158
2.5 5620 12,033
2.25 5058 11,930
2.25 5058 11,884
2.25 5058 11,763
2.25 5058 11,714
2 4496 11,538
2.5 5620 11,424
2.5 5620 11,373
2.25 5058 11,337
2 4496 11,299
2.5 6180 11,244
2.25 5058 11,045
2.5 5620 10,923
2 4496 10,423
2 4496 10,308
2 4496 10,212
2.75 6798 9,746
2.5 5620 9,113
1.25 3090 8,606
4 8992 19,234
3 6744 14,026
2.75 6182 13,809
2.75 6182 13,398
3 6744 12,824
2.5 5620 12,613
2.5 6180 12,250
2.25 5058 12,002
2.5 5620 12,697
2.5 6180 15,023
3 6744 13,901
5.75 14214 24,917
5.25 11802 24,224
3.25 8034 17,239
5.25 12978 21,756
3.25 8034 17,395
3.75 8430 17,135
3 7416 16,130
3.25 7306 15,970
3.25 7306 15,809
3 7416 15,787
3.25 8034 15,146
3.25 8034 14,914
3 6744 14,739
3 6744 14,310
3 7416 14,180
3.25 8034 14,131
2.75 6182 14,107
2.25 5058 13,878
2.75 6798 13,738
3 6744 13,528
2.5 6180 13,384
2.25 5562 12,905
2.75 6182 12,886
2.5 5620 12,705
2.75 6182 12,697
2.75 6182 12,608
2.75 6182 12,601
2.5 5620 12,578
2.5 6180 12,532
3.25 7306 12,482
2.25 5058 12,351
2.25 5058 12,144
2.5 5620 12,080
2.25 5058 11,824
2.5 6180 11,759
2.25 5058 11,642
2.5 5620 11,640
2.5 5620 11,500
2.25 5562 11,369
2.25 5058 10,956
2.5 5620 10,687
2 4496 10,251
2 4496 10,178
2.5 5058 10,167
2.25 5058 9,899
2 4944 9,528
2 4944 9,346
1.75 4326 9,176
3.25 8034 15,451
3 6744 14,359
3.25 7306 14,193
2.75 6182 13,305
2.5 5620 13,238
2.5 5620 13,100
2.75 6182 12,053
2 4496 11,832
2 4496 11,168
2 4496 10,936
3.25 8034 15,983
2 4944 10,981
2.5 6180 10,032
1.5 3372 6,434
5.25 11802 24,082
5.25 12978 25,396
2.5 5620 13,138
3.75 9270 18,240
3.5 8652 17,433
3.75 8430 16,813
3.75 9270 16,155
Average
3.25
2.75
2.75
3.25
2.75
3
2.75
2.75
3.25
2.75
2.5
2.5
2.5
3
3
2.75
3
2.25
2.25
2.25
2.75
2.75
2.5
2.5
2.75
2.75
2
1.75
2.74
8034
6798
6182
7306
6182
6744
6182
6798
7306
6182
5620
5620
6180
6744
6744
6182
6744
5562
5562
5058
6182
6182
6180
5620
6182
6182
4944
4326
6,344
15,250
14,314
13,942
13,938
13,855
13,845
13,747
13,692
13,630
13,436
13,212
13,020
12,839
12,643
12,309
12,227
12,224
12,148
12,003
11,977
11,816
11,803
11,474
11,473
11,335
10,844
10,740
9,604
13,175
Table 30. Boston Medical Center ACL Surgery Data From Dr. William Creevy.
